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ABSTRACT 
Interaction of bilirubin (BR) with cells or cell membranes is well documented 
and it is commonly accepted that the toxicity of bilirubin depends on its passage 
across the plasma membrane and its association with the membrane lipids. 
However, the way in which bilirubin interacts with biological membranes is not 
fully understood. Erythrocytes, being simple, have been commonly used as a 
model system to study the interaction of bilirubin with cells or cell membranes. 
Further, erythrocyte-bound bilirubin has been suggested as a useful criterion for 
the risk of bilirubin encephalopathy in neonates. 
Although a large number of data is available on the bilirubin-membrane 
interaction, no conclusion has been arrived at the mechanism of entry and 
localization of bilirubin in the bilayer membranes. It appears that more studies 
are required to confirm the localization of bilirubin in the erythrocyte membranes 
in terms of surface binding, internal binding, hydrophobic binding, etc. Though, 
the presence of bilirubin binding sites on biological membranes has been 
suggested, characterization of the individual membrane component involved in 
binding and the location of the binding sites on the erythrocyte membranes have 
not been fully worked out. 
Contradictory results achieved so far regarding the mechanism of entry of 
bilirubin into erythrocyte membranes calls for reinvestigation of bilirubin binding 
properties of membrane. To unravel the mechanism of entry of bilirubin into 
brain cells, we have performed studies on the interaction of bilirubin with normal 
II 
and altered humjin erythrocyte membranes as a model. The identification and 
characterization of bilirubin binding receptors on eiythrocyte membranes may 
form the basis for the development of various preventive measures against 
bilirubin encephalopathy. 
Interaction of bilimbin with different aged group red cell membranes showed 
maximum binding to old erythrocyte membranes and minimum with young 
erythrocyte membranes and this difference corresponds negatively with sialic 
acid content and phospholipid content of these membranes probably due to 
decreasing surface charge density with age. facilitating the penetration of 
bilimbin into these old membranes. 
The effect of pH and temperature on the binding of bilirubin to human 
erythrocyte membranes was studied by incubating the membranes at different pH 
and temperatures, and determining the amount of bound bilirubin. Binding of 
bilirubin to erythrocyte membranes is independent of the ionic strength of the 
incubation mixtuire however, changes in pH greatly affects membrane-bound 
bilirubin. At all pH values, the amount of membrane-bound bilirubin increased 
with the increase in bilirubin-to-albumin molar ratios (B/As), being highest at 
lower pH values in all cases. Further, linear increase in boimd bilirubin with the 
increase in bilirubin concentration in incubate was observed at a constant B/A 
and at all pH values. However, the value of slope increased with decrease in pH 
suggesting more bilirubin binding to membranes at lower pH values. Increase in 
bilirubin binding at lower pH can be explained on the basis of increased free 
01 
bilirubin concentration as well as more conversion of bilirubin dianion to 
monoanion. 
Temperature dependence of bilirubin binding to membranes was observed 
within the temperature range of 7°-60°C, showing minimum binding at 27°C and 
31°C, which increased on either side. Increase in bilirubin binding at temperature 
lower than 20°C and higher than 40°C can be ascribed to the change in 
membrane topography as well as bilirubin-albumin interaction. 
Interaction of bilirubin with different types of erythrocyte membrane vesicles 
such as unsealed, heterogeneous, sealed and inside-out membrane vesicles 
prepared from hiunan and goat erythrocytes were studied. Bilirubin binds to both 
the surfaces of erythrocyte membranes and also accumulates within the lipid 
bilayer of the er^^ocyte membrane, which cannot be removed by albumin. Out 
of various types of membrane vesicles, in both species, unsealed membrane 
vesicles bound quantitatively higher amounts of bilirubin followed by 
heterogeneous and sealed membrane vesicles whereas inside-out membrane 
vesicles bound the lowest amount of bilirubin. 
These differences in the amount of bound bilirubin to different membrane 
vesicles were correlated well with the percentage accessibility of sialic acid to 
neuraminidase in these membranes suggesting that bilirubin bound preferentially 
to the outer layer of erythrocyte membranes than the iimer layer. Further, 
membrane vesicles prepared from human erythrocytes bound higher amounts of 
bilirubin than those prepared from goat erythrocytes. This can be ascribed to 
different phospholipid composition of these membranes. 
IV 
Binding of bilirubin to human erythrocyte membranes was studied after 
various enzymatic treatments as well as calcium loading. Whereas phospholipase 
D treatment of erythrocyte membranes resulted in 23% increase in bilirubin 
binding, phospholipase C-treated membranes showed remarkable enhancement 
in bilirubin binding. Polar head groups in general and negatively charged 
phosphate moieties, in particular, of phospholipids of the membrane appear to 
inhibit a large amount of bilirubin from binding to the membranes. 
Neuraminidase treatment of the membranes also led to a slight increase in 
bilirubin binding as compared to untreated membranes. Membrane proteins and 
carbohydrates seem to play significant regulatory role in bilirubin binding. 
However, no direct correlation was found between the increase in bilirubin 
binding and the amount of carbohydrate released upon tryptic digestion of 
membranes. Increase in bilirubin binding to trypsin-treated membranes can be 
ascribed to the increase in free bilirubin concentration in the incubation mixture 
as a result of tryptic hydrolysis of albumin by the membrane-bound tryptic 
activity. Calcium-loaded erythrocyte membranes also showed remarkable 
increase in bilirubin binding as a result of negative charge shielding and calcium-
induced hydrophobic aggregation. These results suggest the mhibitory role of 
polar head groups of phospholipids (phosphate in particular), carbohydrate and 
sialic acid in the binding of bilirubin to erythrocyte membranes. 
In order to study the role of membrane proteins in bilirubin binding 
phenomenon, selective removal of membrane proteins was carried out using 
various reagents, namely, ethylenediamine tetraacetic acid (EDTA), sodium 
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hydroxide (NaOH), 3,5-diiodosalicylic acid, lithium salt (LIS), dimethylmaleic 
anhydride (DMMA), sodium iodide (Nal), o-phenanthroline-cupric sulfate (CuP) 
and phenanthroline-cupric sulfate reduced with 2-mercaptoethanol. Effects of 
these treatments on the conformation and bilirubin binding properties of the 
membrane were studied using CD spectroscopy as well as estimation of 
membrane-bound bilirubin by diazotized-color reaction. Though a significant 
amount of protein (ranging from 23 % to 69 %) was lost from the membranes 
upon these treatn:ients, only a small decrease (3-13 %) was observed in bilirubin 
binding, being maximum with NaOH-treated membranes. 
However, DMMA and Nal treatments produced a little increase in bilirubin 
binding. Conformation of the membrane was retained to a significant extent as 
indicated by far-UV CD spectra upon these treatments except in DMMA and Nal 
treatments which resulted in the perturbation in CD spectra. Taken together, 
these results suggest that membrane proteins play little role in bilirubin binding, 
rather act as barriers in bilirubin binding phenomenon. 
Further, to study the mechanism of entry and localization of bilirubin into 
membrane, binding of bilirubin to sealed and human serum albumin (HSA)-
entrapped sealed membranes was studied by CD spectroscopy. An induced 
bisignate CD cotton effect (CDCE) of bilirubin-bound sealed membrane complex 
is observed with maxima at 515 imi and broad minima at around 430-470 nm. 
The bilirubin-bound HSA-entrapped sealed membrane complex shows a 
bisignate CDCE with positive peaks at 450 nm and 475 nm and negative troughs 
at 390 nm and 415 nm. 
VI 
The induced CDCE of BR-membrane protein and BR-HSA complex was 
perturbed by the addition of drugs (ceftriaxone and sodium salicylate) with the 
effect of ceftriaxone in bilirubin displacement being more potent. Drugs, being 
the displacer of BR from albumin, their presence in the incubation mixture was 
paralleled by reduction in CDCE. Thus, it seems that the CDCE observed is in 
fact that of BR-HSA complex, suggesting the availability of bilirubin to the 
internalized albumin. These results suggest that bilirubin can traverse the 
membrane bilayer towards the inner surface instead of remaining intercalated in 
the exterior half of the bilayer. 
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ABSTRACT 
Interaction of bilirubin (BR) with cells or cell membranes is well documented 
and it is commonly accepted that the toxicity of bilirubin depends on its passage 
across the plasma membrane and its association with the membrane lipids. 
However, the way in which bilirubin interacts with biological membranes is not 
fully understood. Erythrocytes, being simple, have been commonly used as a 
model system to study the interaction of bilirubin with cells or cell membranes. 
Further, erythrocyte-bound bilirubin has been suggested as a usefiil criterion for 
the risk of bilirubin encephalopathy in neonates. 
Although a large number of data is available on the bilirubin-membrane 
interaction, no conclusion has been arrived at the mechanism of entry and 
localization of bilirubin in the bilayer membranes. It appears that more studies 
are required to confirm the localization of bilirubin in the erythrocyte membranes 
in terms of surface binding, internal binding, hydrophobic binding, etc. Though, 
the presence of bilirubin binding sites on biological membranes has been 
suggested, characterization of the individual membrane component involved in 
binding and the location of the binding sites on the erythrocyte membranes have 
not been fully worked out. 
Contradictory results achieved so far regarding the mechanism of entry of 
bilirubin into erythrocyte membranes calls for reinvestigation of bilirubin binding 
properties of membrane. To unravel the mechanism of entry of bilirubin into 
brain cells, we have performed studies on the interaction of bilirubin with normal 
II 
and altered human erythrocyte membranes as a model. The identification and 
characterization of bilirubin binding receptors on erythrocyte membranes may 
form the basis for the development of various preventive measures against 
bilirubin encephalopathy. 
Interaction of bilirubin with different aged group red cell membranes showed 
maximum binding to old erythrocyte membranes and minimum with young 
erythrocyte membranes and this difference corresponds negatively with sialic 
acid content and phospholipid content of these membranes probably due to 
decreasing surface charge density with age. facilitating the penetration of 
bilirubin into diese old membranes. 
The effect of pH and temperature on the binding of bilirubin to human 
erythrocyte membranes was studied by incubating the membranes at different pH 
and temperatures, and detennining the amount of bound bilirubin. Binding of 
bilirubin to erythi'ocyte membranes is independent of the ionic strength of the 
incubation mixture however, changes in pH greatly affects membrane-bound 
bilirubin. At all pH values, the amount of membrane-bound bilirubin increased 
with the increase in bilirubin-to-albumin molar ratios (B/As), being highest at 
lower pH values in all cases. Further, linear increase in bound bilirubin with the 
increase in bilimbin concentration in incubate was observed at a constant B/A 
and at all pH values. However, the value of slope increased with decrease in pH 
suggesting more bilirubin binding to membranes at lower pH values. Increase in 
bilirubin binding at lower pH can be explained on the basis of increased free 
I l l 
bilirubin concentration as well as more conversion of bilirubin dianion to 
monoanion. 
Temperature dependence of bilirubin binding to membranes was observed 
within the temperature range of 7°-60°C, showing minimum binding at 27°C and 
37°C, which increased on either side. Increase in bilirubin binding at temperature 
lower than 20°C and higher than 40°C can be ascribed to the change in 
membrane topography as well as bilirubin-albumin interaction. 
Interaction of bilirubin with different types of erythrocyte membrane vesicles 
such as unsealed, heterogeneous, sealed and inside-out membrane vesicles 
prepared from human and goat erythrocytes were studied. Bilirubin binds to both 
the surfaces of erythrocyte membranes and also accumulates within the lipid 
bilayer of the erythrocyte membrane, which cannot be removed by albumin. Out 
of various types of membrane vesicles, in both species, unsealed membrane 
vesicles bound quantitatively higher amounts of bilirubin followed by 
heterogeneous and sealed membrane vesicles whereas inside-out membrane 
vesicles bound the lowest amount of bilirubm. 
These differences in the amount of bound bilirubin to different membrane 
vesicles were correlated well with the percentage accessibility of sialic acid to 
neuraminidase in these membranes suggesting that bilirubin bound preferentially 
to the outer layer of erythrocyte membranes than the inner layer. Further, 
membrane vesicles prepared Jfrom human erythrocytes bound higher amounts of 
bilirubin than those prepared from goat erythrocytes. This can be ascribed to 
different phospholipid composition of these membranes. 
IV 
Binding of bilirubin to human erythrocyte membranes was studied after 
various enzymatic treatments as well as calcium loading. Whereas phospholipase 
D treatment of erythrocyte membranes resulted in 23% increase in bilirubin 
binding, phospholipase C-treated membranes showed remarkable enhancement 
in bilirubin binding. Polar head groups in general and negatively charged 
phosphate moieties, in particular, of phospholipids of the membrane appear to 
inhibit a large amount of bilirubin from binding to the membranes. 
Neuraminidase treatment of the membranes also led to a slight increase in 
bilirubin binding as compared to untreated membranes. Membrane proteins and 
carbohydrates seem to play significant regulatory role in bilirubin binding. 
However, no direct correlation was found between the increase in bilirubin 
binding and the amount of carboh\'drate released upon tryptic digestion of 
membranes. Increase in bilirubin binding to trypsin-treated membranes can be 
ascribed to the increase in free bilirubin concentration in the incubation mixture 
as a result of tryptic hydrolysis of albumin by the membrane-bound tryptic 
activity. Calcium-loaded erytlirocyte membranes also showed remarkable 
increase in bilirubin binding as a result of negative charge shielding and calcium-
induced hydrophobic aggregation. These results suggest the inhibitory role of 
polar head groups of phospholipids (phosphate in particular), carbohydrate and 
siahc acid in the binding of bilirubin to erythrocyte membranes. 
In order to study the role of membrane proteins in bilirubin binding 
phenomenon, selective removal of membrane proteins was carried out using 
various reagents, namely, ethylenediamine tefraacetic acid (EDTA), sodium 
V 
hydroxide (NaOH), 3,5-diiodosalicylic acid, lithium salt (LIS), dimethylmaleic 
anhydride (DMMA), sodium iodide (Nal), o-phenanthroline-cupric sulfate (CuP) 
and phenanthroline-cupric sulfate reduced with 2-mercaptoethanol. Effects of 
these treatments on the conformation and bilirubin binding properties of the 
membrane were studied using CD spectroscopy as well as estimation of 
membrane-bound bilirubin by diazotized-color reaction. Though a significant 
amount of protein (ranging from 23 % to 69 %) was lost from the membranes 
upon these treatments, only a small decrease (3-13 %) was observed in bilirubin 
binding, being maximum with NaOH-treated membranes. 
However, DMMA and Nal treatments produced a little increase in bilirubin 
binding. Conformation of the membrane was retained to a significant extent as 
indicated by far-UV CD spectra upon these treatments except in DMMA and Nal 
treatments which resulted in the peiturbation in CD spectra. Taken together, 
these results suggest that membrane proteins play little role in bilirubin binding, 
rather act as barriers in bilirubin binding phenomenon. 
Further, to study the mechanism of entry and localization of bilirubin mto 
membrane, binding of bilirubin to sealed and human serum albiunin (HSA)-
entrapped sealed membranes was studied by CD spectroscopy. An induced 
bisignate CD cotton effect (CDCE) of bilirubin-bound sealed membrane complex 
is observed with maxima at 515 nm and broad minima at around 430-470 nm. 
The bilirubin-bound HSA-entrapped sealed membrane complex shows a 
bisignate CDCE with positive peaks at 450 nm and 475 nm and negative troughs 
at 390 imi and 415 imi. 
VI 
The induced CDCE of BR-membrane protein and BR-HSA complex was 
perturbed by the addition of drugs (ceftriaxone and sodium salicylate) with the 
effect of ceftriaxone in bilirubin displacement being more potent. Drugs, being 
the displacer of BR from albumin, their presence in the incubation mixture was 
paralleled by reduction in CDCE. Thus, it seems that the CDCE observed is in 
fact that of BR-HSA complex, suggesting the availability of bilirubin to the 
internalized albumin. These results suggest that bilirubin can traverse the 
membrane bilayer towards the inner surface instead of remaining intercalated in 
the exterior half of the bilayer. 
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Figure 36. Visible-CD spectra of (a) free membrane and (b) free 144 
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containing 1 mM MgS04 
Figure 37. Visible-CD spectra of (A) bilirubin-bound sealed membrane, 146 
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INTRODUCTION 
Heme catabolism in the reticuloendothelial cells of liver, spleen and bone 
marrow leads to the fomiation of bilirubin as the final product. Under 
physiological conditions, in human adult (70 Kg), 6 g of hemoglobin equivalent 
to 1-2x10^ erythrocytes is destroyed per day producing 250-350 mg of bilirubin 
(Schmid & McDonagh, 1978). Approximately 3-4 mg bilirubin/Kg of body 
weight is produced per day in healthy adult. In infants, production of bilirubin is 
high (6-8 mg/Kg body weight) because of greater erythrocyte mass and shorter 
life span of erythrocytes (Gourley, 1997). Both proteins globin and iron, of 
hemoglobin are reutilized by the body, but the iron-free porphyrin portion of 
heme is catabolized into bilirubin IX-a. Bilirubin IX-a can be isolated from 
gallstone and is the most commonly found natural linear tetrapyrole. In plasma, it 
is firmly bound to serum albumin in a molar ratio of 1:1 and rendered non-toxic 
(Bratlid& Fog, 1970). 
PROPERTIES OF BILIRUBIN 
(i) Structure: Protoporphyrin IX, the catabolic product of hemoglobin, 
opens at the a-methin bridge and leads to the formation of bilirubin IX-a (Z,Z) 
(Figure 1, i). This is the main component of bilirubin in the body, which is 
neurotoxic (Brodersen, 1980). It has a polar structure with several groups capable 
of forming hydrogen bonds, namely two carboxyls, two pyrrol NH, two lactam-
NH, two lactam carbonyls and several hydrophobic groups i.e. four methyls, two 
vinyls, two ethylenes and one methylene (Figure 1, ii). Bilirubin IX-a (Z,Z) 
exists either as dianion or intramolecularly hydrogen-bonded bilirubin acid (as 
shown in Figure 1, iii & iv). Illumination of bilirubin IX-a (Z,Z) with blue light 
causes cis-trans isomerization (Figure 1, ii) and leads to the formation of 
photobilirubins, namely bilirubin IX-a (E,Z) or bilirubin IX-a (E,E) (Lightner & 
Park, 1977; Pedersen et al., 1977) which no longer form intramolecular hydrogen 
bonds. Small amounts of protoporphyrin IX are opened at 3 position and still 
smaller at y and 5 (Figure 1, i) leading to the formation of various non-a isomers 
(IX-P, IX-y and lX-5) constituting 5 % of total bilirubin (Blanckart et al, 1975; 
Brown, 1976; Blumenthal et al, 1977). 
(ii) Solubility: Bilirubin IX-a (Z,Z) is nearly insoluble in water at pH values 
below 7.0 but is quite soluble in alkaline solutions forming salts of the dianion 
i.e. solubility increases markedly from acidic to alkaline pH values (Brodersen, 
1980). Non-a isomers, on the other hand, are more soluble in water (Overbeek et 
al., 1955; Brodersen, 1979) even in acid solution. Poor solubility of the a-isomer 
in (Z,Z) configuration is due to the presence of undissociated carboxyl groups 
capable of formuig a complete pattern of intramolecular hydrogen bonds (Figure 
1, iv). At pH 7.4, ionic strength 0.15 and 37°C, solubility of pure IX-a isomer of 
bilirubin is found to be 7 nM, whereas it is 0.60 [xM in alkaline aqueous media at 
pH 8.5 (Brodersen, 1979). The solubility of bilirubin in apolar solvents, such as 
n-hexane is less than 1 |iM and generally increases with increasing solvent 
polarity, reaching to a value higher than 10 mM in dimethyl sulfoxide 
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Figure 1. Chemical structure of bilirubin 
(i) Protopoq)hyrin IX (ii) Bilirubin IX-a (Z,Z) 
(iii) BilirubinlX-a (dianion) 
(iv) Bilirubin IX-a acid, intramolecularly hydrogen bonded 
(Adapted from Brodersen, 1979). 
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(Adapted from Brodersen, 1979). 
(Brodersen, 1979). Earlier bilirubin was considered to be a lipophilic substance, 
based on the binding of bilirubin to lipid-water interphases containing lipids of a 
polar nature (Mustafa & King (1970). Minimum aqueous solubility at 
physiological pH (Ostrow et al., 1994) due to formation of intramolecular 
hydrogen bonds (Bonnett et ai, 1978) can account for another speculative factor 
for bilirubin lipophilicity. According to its solubility characteristics, bilirubin is a 
polar substance and could hardly be rated as lipophilic (Brodersen, 1979). 
Chemical nature of bilirubin shows limited amount of lipophilic carbon hydride 
moieties but several strongly polar groups, i.e. two lactam and two carboxyl 
groups and the dianion forms a water soluble sodium salt which occurs as a 
monomer-dimer equilibrium mixture (Brodersen, 1966) but shows no tendency 
to micelle formation in alkaline solution. 
(iii) Spectroscopic properties: Light absorption spectrum of bilirubin IX-a 
(Z,Z) acid, dissolved in organic solvents shows two maxima, one weak band at 
about 290 nm and another intense maximum at 450-460 nm (Heilmeyer, 1931), 
while spectrum of non-a isomers of bilirubm m dim ethyl-formamide solution 
shows similar maximum although the main peak is located at shorter wavelength 
390-410 nm (Blanckaert et al, 1976). Bilirubin IX-a (Z,Z) acid has a molar 
absorption coefficient close to 60,000 M"'cm"' at 460 nm in chloroform 
(Brodersen, 1979). Dilute solutions of bilirubin disodium salt in alkaline aqueous 
media have light absorption maximum around 430-440 nm, depending upon 
buffer composition and temperature (Carey & Koretsky, 1979). The molar 
absorption coefficient has been reported to be in the range of 4.7-5.2x 10"* M'^cm' 
(Blauer et al., 1972; Carey & Koretsky, 1979; McDonagh, 1979). The spectrum 
is constant with pH varying from 8-12. At low concentrations of bilirubin, from 
about 20 nM to an upper limit between 1-10 }j.M, the scattering to high values, 
indicates formation of large particles. The light absorption spectrum shows a 
slight, immediate loss of intensity followed by marked decrease of the peak at 
440 nm and an increase in absorption at 500 nm with increasing time. 
(iv) Bilirubin catabolism in vivo: Bilirubin is albumin-bound in plasma. 
Small amount of bilirubin is also conjugated with glucose (Blanckaert e{ al, 
1974) and xylose (CompemoUe et al., 1971; Fevery et al., 1977). Albumin-
bound bilirubin is removed from albumin in liver, taken up at the sinusoidal 
surface of the hepatocytes by a carrier-mediated saturable system. The smooth 
endoplasmic reticulum provides a set of enzymes, which convert bilirubin into 
diglucuronide. Similar conversion also occurs in kidney and intestinal mucosa. 
Secretion of this conjugated bilirubin into bile is carried out by an active 
transport mechanism. As the conjugated bilirubin reaches the terminal ileum and 
large intestine, the glucuronides are removed by specific bacterial enzymes and 
the pigment is reduced by the fecal flora to a group of colorless tetrapyrrolic 
compounds, called urobilins and fmally excreted in the feces (Schmid & 
McDonagh, 1978; Kitamurae/a/., l990;Nishidaera/., 1992). 
FUNCTIONS OF ALBUMIN 
About 40 % of the albumin is found in the circulatory plasma (Peters, 1992) 
whereas remaining 60 % resides about half in vicera and half in muscle and skin 
(Rabilloud et al, 1988). Albumin is reported to occur intracellularly in 
developing brain tissue (Pineiro et al, 1982), nerve cells (Mata et al., 1987) and 
both interstitially and intracellularly, in testis (Krishna & Spanel-Borowski, 
1990). The albumin concentration in plasma in an average person is about 35-50 
g/L, which declines slightly with age (Cooper & Gardner, 1989) and is lower in 
newborns (Cartlidge & Rutter, 1986) and as low as 20 g/L in premature infants 
(Reading ei ai, 1990). Albumin performs many vital functions while circulating 
in blood plasma. Along with the maintenance of blood pH, it contributes -80 % 
to the colloidal osmotic pressure (Figge et al., 1991). It is involved in the 
transport of many ligands including Ca"* (Vorum et al., 1995), long fatty acids 
(Brodersen & Ebbesen, 1983; Peters, 1985), thyroid hormones (Mendel et al., 
1990), tryptophan (Herve et al., 1982; Zhang et al., 1993) through reversible 
binding. It is also involved in the transport of pyridoxal phosphate (Fonda et al., 
1991), cysteine and glutathione (Joshi et al., 1987) by forming covalent linkage 
with these ligands. The tight binding of bilirubin to albumin (Knudsen et al., 
1986) prevents the passage of this neurotoxic pigment into the central nervous 
system in newborns (Esbjomer, 1991) and helps in its delivery to the liver for 
conjugation and excretion. Antioxidant property of albumin-bound bilirubin has 
also been reported (Stocker et al., 1987). Whereas bilirubin causes increase in 
fluidity of the erythrocyte membrane, albumin prevents the fluidity changes in 
erythrocyte membranes (Chen et ai, 1992). The participation of albumin as the 
key carrier of an incredible variety of ligands serves to illustrate further the 
continuing recognition of the utility of albumin (Stamler et ai, 1992). Albumin is 
responsible for the transport and storehousing of many therapeutic drugs in the 
blood stream (Lindup, 1987). 
ALBUMIN-LIGAND INTERACTION 
A variety of endogenous as well as exogenous ligands bind to albumin in a 
reversible manner with association constant varying from 10''-10^ M"' (Carter & 
Ho, 1994). Some important informations regarding the binding sites have been 
gained from the recently determined crystal structure of HSA (He & Carter, 
1992; Sugio et ai, 1999). A number of selective binding sites have been shown 
to exist on HSA, which include drug-binding sites, I and II, as well as relatively 
specific sites for bilimbm and fatty acids (Figure 2, a). Although a vast majority 
of ligands bind to the two strong binding sites residing in subdomains 11 A and 111 
A corresponding to the two sites, I and II, respectively (Sudlow et ai, 1976). 
Subdomain 111 A (Site II) seems to possess the primary binding activity of 
albumin while subdomain II A (Site 1) is more specialized (Carter & Ho, 1994). 
The bilirubin-binding site is believed to reside in subdomain HA (Carter & Ho, 
1994). Lys-240 (Site I in subdomain II A) of HSA has been shown to be 
important in forming a salt bridge with carboxyl group of bilirubin (Jacobsen, 
1978) and critical lysine residue(s) is(are) supposed to be buried in the protein 
interior (Tayyab & Qasim, 1987; Mir et al., 1992). About 50 drugs have been 
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Figure 2. (a) Stereo view of the heart shaped structure of human serum 
albumin with overall topology and secondary structure. 
(Adapted from Carter & Ho, 1994) 
(b) 
Half -domains S i t e s 
Bilirubin I 
Fatty acid I + II 
Bilirubin I 
(b) A model of albumin molecule, showing six half-domains which are 
combined to form two sites for binding of bihrubin and one for fatty acids 
(Taken from Brodersen, 1979). According to the new nomenclature, half-
domains AB and C now refer to subdomains A and B, respectively (Carter & 
Ho, 1994). 
11 
found to show competitive binding to bilirubin high affinity site on albumin 
(Brodersen, 1974; Brodersen et al, 1977; Ishimura et al, 1990; Robertson, 
1991). These ligands are anionic, contain aromatic structure and are more or less 
water-soluble. The binding of drugs to plasma proteins may play important role 
in their pharmacokinetics and pharmacological results. Several authors reported 
that albumin is the protein contributing most of these interactions (Kragh-
Hansen, 1981). The differences in the binding percentages of various ligands 
have been reported to be due to greater affmity and not the existence of 
additional sites. 
BILIRUBIN-ALBUMIN INTERACTION 
Bilirubin exists in serum in either free form (unconjugated bilirubin), or 
conjugated form (monoglucuronide and diglucuronide bilirubins) or bound to 
albumin (Kurosaka et al, 1998). The reaction of bilirubin with human serum 
albumin was first quantitated by equilibrium dialysis (Martin, 1949). Albumin 
has one strong (primary site) and one weak bilirubin binding site (Figure 2, b) but 
only the primary binding site is of physiological importance because of the safe 
delivery of the bound pigment to the liver (Peters, 1992). High affinity bilirubin 
binding site resides near loop 4 of subdomain II A. Bilirubin at the primary site 
binds in a highly specific way in the form of dianion. One molecule of bilirubin 
is bound v^th high affinity (Ka=1.4x 10^  L/mole) and two additional molecules of 
the pigment bind with lower affinity (Ka=5.0xl0^ L/mole) (Jacobsen, 1969). 
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Only the binding at fu-st site is strong enough to prevent bilirubin from entering 
central nervous system of neonates and causing kemicterus (Brodersen, 1979). 
The binding affinity of bilirubin to serum albumin has been reported to be 
independent of pH from 7.0 to 9.0 (Wennberg & Rasmussen, 1978; Brodersen, 
1979). However, albumin does not bind bilirubin above pH 12.0 because of 
unfolding of albumin below pH 7.0 and due to insolubility of bilirubin at low pH. 
Further, the affmity of bilirubin binding to albumin for primary binding site has 
been found to decrease with increasing temperature and ionic strength (Jacobsen, 
1977). This suggests the role of electrostatic interactions in the binding. Kinetic 
studies have revealed that the binding is rapid followed by several relaxation 
steps of conformational changes as seen in the light absorption spectra of 
bilirubin upon binding to albumin (Jacobsen & Brodersen, 1983). Binding of 
bilirubin to albumin has been studied using circular dichroism (CD), nuclear 
magnetic resonance (NMR) and absorption spectroscopy (Harmatz & Blauer, 
1975; Kaplan & Navon, 1981; 1982; 1983; Lightner et al, 1986; 1988) but the 
conformation of bound bilirubin and nature of binding site on albumin remains 
poorly understood. 
Bilirubin in solution exists in two enantiomeric coirformations M and P, which 
are in dynamic equiUbrium as shown in Figure 3 (Manitto & Monti, 1976; 
Kaplan & Navon, 1983). Albumin binds exclusively to one of the enantiomers 
depending on the species chosen and induces circular dichroism (CD) in the 
visible region, in the bound bilirubin. The induced-CD spectra is characterized by 
the bisignate CD Cotton effects (CDCEs) or monosignate CDCE usually of 
Figures. The two ridge-tile confomiationai enantiomers of bilirubin. 
The double-headed arrows passing through the dipyrrinone chromophores 
indicate the orientation of electronic transition dipoles of each 
dipyrrinone. Insets show the relative helicities (M, minus or P, plus) of the 
dipoles (Boiadjiev & Lightner, 1997). 
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longer wavelength and negative sign (Harmatz & Blauer, 1975). In case of 
bilirubin complexed with HSA, CD spectra is characterized by the bisignate 
CDCEs having minima (-) at shorter wavelength and maxima (+) at longer 
wavelength (Hannatz & Blauer, 1975; Blauer et ai, 1977; Lightiier et al, 1986; 
1988). Bisignate CDCEs thus seem to be characteristic of either a 
bichromophoric pigment complexed to the protein complex containing two 
chromophores which are not covalently linked to each other but which 
presumably bear proximal relationship (Lightner et al, 1986). The observed 
bisignate CDCEs are due to chromophore-chromophore interaction of the two 
locally excited states of the twin pyrromethanone chromophores i.e. exciton-
splitting (Harada & Nakashami, 1983). The sign order in a bisignate CD 
spectrum depends on the relative helical orientation of two pyrromethanone 
electric dipole moments. A right-handed helicity (positive {P) chirality) of the 
transition moments generates a (+) longer wavelength Cotton effect followed by 
a (-) shorter wavelength Cotton effect as observed in case of bilirubin-HSA 
complex. On the other hand, left handed helical orientation (negative {M) 
chirality) of the electric dipole moments produces inverted CDCEs (Harada & 
Nakanishi, 1983) as observed in case of bilirubin-BSA complex (Harmatz & 
Blauer, 1975). It has been concluded that the interaction of only one of the two 
carboxyl groups of bilirubin with a single positively charged amino acid residue, 
such as arginine or lysine, is required to maintain the ridge tile bilirubin 
conformation observed with bilirubin-HAS complex (Petersen et al., 2000). 
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BILIRUBIN TOXICITY AND BILIRUBIN ENCEPHALOPATHY 
Bilirubin belongs to a class of substances usually termed cholephilic organ 
anions, because their concentration is 10-1000-fold higher in bile than in blood 
(Klassen & Watldn, 1984). When bilirubin concentration in plasma exceeds 10 
mg/L, hyperbilirubinemia exists and over 350 mg/L, the bilirubin fixation 
capacity of plasma is overloaded and bilirubin diffuses from the plasma to the 
tissues, which become yellow, a condition known as jaundice or icterus 
(Scharschmidt, 1988). The safe upper limit i.e., the threshold for neurotoxicity, of 
unbound bilirubin is reported to be >20 nmol/L for low birth weight infants 
(Cashore & Oh, 1982). In hyperbilirubinemic infants, particularly when total 
bilirubin exceeds 200 jimol/L, unbound bilirubin usually increases to >10 
mmol/L (Ihara et ai, 1987). Maintenance of unbound bilirubin below 20 nmol/L 
is important for prevention of icterus-associated neurological deficits. Schmorl 
(1904) suggested the term Tcemicterus' for yellow staining of basal ganglia in 
association with neonatal jaundice. This term has been used, since then to 
describe both the acute, often fatal seizures, opisthotomes and bleeding tendency 
as well as the neurologic sequelae in survivors, consisting of choreoathetosis, 
asymmetric spasticity, paresis of upward gaze and neurogenic hearing loss 
(Byers et ai, 1955; Perlstein, 1960; Hyman et al, 1969; Keaster et ai, 1969; 
Fenwick, 1975). But now-a-days, the term 'kemicterus' is replaced by another 
term 'bilirubin encephalopathy' which includes all conditions where bilirubin is 
known or thought to be the cause of brain toxicity (Hansen and Bratlid, 1986). 
Neonatal jaundice is a common transitional phenomenon, which is due to 
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combination of increased heme catabolism and rate limitations as well as hepatic 
conjugation and biliary excretion of bilirubin (Hansen, 2000). 
Free unconjugated bilirubin is a potentially cytotoxic substance (Metze, 1977). 
Its damaging effects are seen not only on the cells of nervous system but also in 
other cell types and tissues e.g. heart, kidney, Langerhan's islets of pancreas, 
liver, platelets and teeth (Metze, 1977). Bilirubin might be toxic to immune 
system cells, lymphocytes and granulocytes (Miler et ai, 1985). Several enzyme 
systems are influenced (Karp, 1979; Amit & Boneh, 1993) as inhibitory effects 
of bilirubin on the binding of cAMP to protein kinase are reported (Morphis et 
ai, 1982). In cultured human fibroblasts, bilirubin combined with phototherapy 
induces sfrand breakage in DNA (Rosenstein et ai, 1983; Rosenstein & Ducore, 
1984). Increased entry of bilirubin into brain is associated with reduced bilirubin 
binding capacity of albumin due to the presence of displacing agents and opening 
of blood brain barrier due to hyperosmolality, hypercarbia and asphyxia. 
Recently, in experimental animals, albumin-bound bilirubin has been observed to 
enter the brain and further aggravates the risk of bilirubin encephalopathy, which 
may be facilitated by slight opening of blood brain barrier (Hansen & Bratlid, 
1986; Hansen et ai, 1987; 1989; Hansen, 1996). 
The effects of bilirubin on neurophysiologic processes have only been studied 
to a limited extent. It has been observed that in the cells, bilirubin is bound to 
enzyme carrying membranes such as those of mitochondria (Brodersen, 1979). It 
shows wide spread effects on protein phosphorylation by inhibiting various 
enzymes, namely cAMP-, cGMP-, Ca '^^ -calmodulin- and Ca^ ^ -phospholipid 
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dependent protein kinases (Hansen et al, 1996). It also inhibits phosphorylation 
of histones in the brain of 3-4 days old rabbit (Morphis et al., 1982). 
Nature of bilirubin involved in bilirubin cell toxicity is stiU a controversy. It 
has been suggested that kemicterus and bilirubin toxicity are caused by the 
bilirubin-albumin complex crossing a disrupted blood-brain barrier and that the 
level of free bilirubin or nature of bilirubin binding may not be important in the 
development of bilirubin encephalopathy (Levine et al, 1982). On the other 
hand, studies on the effects of bilirubin on respiration and viability in cell 
cultures have shown that toxicity increases when bilirubin is present in the 
incubate in molar concentrations which exceed that of albumin (Lie & Bratlid, 
1970; Bratlid & Rugstad, 1972). Further, if albumin is present in an equimolar or 
higher ratio with bilirubin, toxicity is blocked (Rasmussen & Wennberg, 1972). 
Now it is well recognized that free, unconjugated bilirubin is the potential 
cytotoxic substance and its damaging effect on the cells of the central nervous 
system in newborns, sujffering from a severe form of hyperbilirubinemia 
(kemicterus) is well known (Odell, 1980; Brodersen & Stem, 1990). It is a 
commonly accepted fact that the toxicity of biltmbin depends on its passage 
across the plasma membrane and its association with membrane lipids (Mustafa 
& King, 1970; Hayward et al., 1986; Noy et al., 1992; Ali & Zakim, 1993; 
Zucker et al., 1994). During the in vitro interaction between bilirubin and cells, 
bilimbin undergoes degradation due to both adsorption to the cells and action of 
cell enzymes (Knobloch & Miler, 1987). Recently, Brites et al. (1997) have 
concluded that tlie first step of eiythrocyte bilirubin toxicity is crenation due to 
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expansion of the outer membrane leaflet by bilirubin monoanion location. This 
effect is more evident in younger cells and explains the protection against the 
hypotonic hemolysis. Insertion of bilirubin deeper into the bilayer, facilitated by 
higher concentration (^1x10"* mol/L) and cell age, produces unstable situation 
where bilirubin acid aggregation is the main cause for hemolysis and cell 
destruction. However, dual character of bilirubin in its biological effects has been 
proposed (McDonagh, 1990). It causes cell damage (Vazquez et al., 1988) on 
one hand but protects cell against oxidative damage on the other hand (Stocker et 
al., 1987; Yesilkaya et al., 1998). Bilirubin may also protect mammals from 
copper poisoning as it acts as an anti-precipitant against copper mediated 
denaturation of BSA by forming a copper-bilirubin complex (Adhikari et al., 
1998). 
BINDING OF BILIRUBIN TO ERYTHROCYTES / ERYTHROCYTE 
MEMBRANES 
In the blood of healthy individuals, unconjugated bilirubin is almost entirely 
bound to albumin. If either the molar concentration of bilirubin exceeds the 
binding capacity of albumin or various competitive inhibitors for bilirubin 
binding to albumin like antibiotics, hormones, sulfonamides, salicylates or other 
drugs are present, the bilirubin may bind additionally to cells of different tissues 
including erythrocytes (Hayer et al., 1989). Binding of bilirubin to erythrocyte 
membrane and biological membranes is well known (Thaler & Wennberg, 1977; 
Bouillerot et al., 1981; Sato & Kashiwamata, 1983; Sato et al., 1987; Gulian et 
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a/., 1987; Wennberg, 1988; Hayer et al, 1989; Amit & Boneh, 1993; Ochoa et 
al, 1993) and has been suggested to be a useful criterion for the risk of bilirubin 
encephalopathy (Bratlid, 1972a). The uptake of bilirubin by erythrocytes has 
been found to be dependent on both bilirubin/albumin molar ratio in the serum 
and total bilirubin concentration (Kaufinann el al., 1967). The bilirubin uptake by 
erythrocytes increases either with the increase in bilirubin concentration while 
bilirubin/albumin molar ratio is constant or with the increase in bilirubin/albumin 
ratio while bilirubin concentration is kept constant (Bratlid, 1972a). However, 
low concentration of bilirubin (10-10" mol/L) protects the erythrocytes against 
hypotonic lysis and leads crenation, while higher bilirubin concentration induces 
hemolysis and leads to membrane disruption (Brites et al., 1997). Bilirubin 
saturated membranes show membrane rupture due to impairment in lipid-lipid, 
protein-protein and lipid-protein interactions. Bilirubin tends to aggregate once 
bound to phospholipids (Gibson & Antonini, 1963) but exists in different states 
when associated with plasma membrane (Glushko et al, 1982). 
Bilirubin binding to erythrocytes takes place within 10 minutes and further 
increase in incubation time does not result in any increase in erythrocyte-bound 
bilirubin (Sato & Kashiwamata, 1983). At a given albumin concentration, 
erythrocytes and albumin bind constant proportions of bilirubin, despite varying 
bilirubin concentrations (Bamhart & Clarenburg, 1973). However, Wennberg & 
Rasmussen (1978) have reported that at equilibrium, the cellular content of 
bilirubin is a function of the concentration of free bilirubin acid and not the total 
bilirubin concentration or bilirubin/albumin molar ratio. 
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The effect of pH on the binding of bilirubin to human erythrocytes has been 
was studied by Bratlid (1972b) and several other workers (Nelson el al., 1974; 
Sato & Kashiwamata, 1983; Wennberg, 1988). Erythrocyte binding of bilirubin 
is increased with decrease in pH and hence, jaundiced neonates with low plasma 
pH have been reported to be at greater risk of developing bilirubin 
encephalopathy (Kim et a!., 1980). In presence of albumin, decrease in pH from 
7.4 to 6.8 results in an increase in erythrocyte-bound bilirubin at all the 
bilimbin/albumin molar ratios, including molar ratios below 1:1 (BratHd, 1972b). 
In the absence of albumin, at higher bilirubin concentrations, there is an increase 
in erythrocyte-bound bilirubin on decreasing pH, although at lower bilirubin 
concentrations, decrease in pH does not affect the erythrocyte-bound bilirubin 
(Bratlid, 1972b). Thus, it appears that bilirubin binding to erythrocytes depends 
on both pH and bilirubin concentration (BratUd, 1972b). Distribution of unbound 
unconjugated bilirubin among body fluids and tissues differs for its three ionic 
species, whose proportions are determined by pH (Ostrow et al, 1994). At pH 
7.4, the fully protonated unconjugated bilirubin (di-acid) is the dominant species 
(83 %) and the monoanion constitutes 16 % but there is less than 1.5 % dianion. 
As pH increases from 7.0 to 8.0, the proportion of unconjugated di-acid declines 
and the proportion of monoanion increases steeply; the proportion of dianion, 
however shows little increase until the pH is above 7.5 and still constitutes only 
17 % of unbound unconjugated bilirubin at pH 8.0 (Ostrow et al, 1994). Most of 
the workers (Zamet & Chunga, 1971; Bratlid, 1972b; Maisels, 1972) are of the 
view that increased cellular binding of bilirubin is due to increased dissociation 
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of bilirubin from the secondary binding sites of albumin occurs at low pH 
without any reduction in the affinity of the primary binding site. Bilirubin is said 
to bind to various structures of cells apart from the cell membrane as evident 
from the lesser binding of bilirubin to cell stroma as compared to intact cells 
(Bratlid, 1972a). Neither storage for one week nor anticoagulant adversely affect 
the ability of erythrocxtes to bind bilirubin. 
Although cellular binding of bilirubin is well-known, multisite toxicity of 
bilirubin towards the metabolism of living cells has not yet been completely 
elucidated. Also, the nature of bilirubin binding to biological membranes and 
pathway(s) through which bilirubin enters into the cells is(are) not fully 
understood. Increased toxicity of bilirubin at a bilirubin/albumin molar ratio 
higher than 1:1 (Lie & Bratlid, 1970; Bratlid & Rugstad, 1972) suggests that it is 
free unbound bilirubin and not albumin-bound bilirubin that binds cell 
membranes. Many workers are of the view that bilirubin diffuses freely through 
biological membranes as it has been found accumulated in the infracellular 
compartments such as mitochondria (Odell, 1966; 1969; Wennberg, 1988). 
Based on the spontaneous leakage of bilirubin from multilamellar liposomes 
(Hayward et al, 1986), it has been proposed that bilirubin is able to difftxse 
through cellular membrane (Weimberg, 1988; Schmidt, 1972) though several 
putative bilirubin transporters have been described (Stremmel & Berk, 1986; 
Kullak-Ublick et al, 1994). Unconjugated bilirubin has been shovm to diffuse 
through model phosphatidylcholine vesicles as the uncharged diacid (Zucker et 
al, 1999) (Figure 4, iv). On the other hand, facihtated mode of bilirubin binding 
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accompanied by a release of phospholipids from the cell membranes favoring the 
bilirubin penetration and aggregation within the membranes has also been 
described (Brito et a/., 1996). Lamola et al. (1979) have shown that bilirubin is 
not solely bound to membranes but that its greater part is present in the cytosol of 
erythrocytes. Contrarily, lysed erythrocyte membranes have been shown to bind 
14 % more bilirubin than intact ghost (Karp et al, 1985). It seems that unlike 
other cells, erythrocytes have all the bilirubin bound to the specific binding sites 
present in the membranes. A binding saturation of 110x10''^ moles of bilirubin 
per erythrocyte and dissociation constant of bilirubin/receptor complexes 
170x 10"^  mol/L (Hayer et al., 1989) has been given, Sato & Kashiwamata (1983) 
have reported apparent dissociation constant (K<i) as 2.3 \xM and maximum 
binding (Bmax) value for the saturable binding of bilirubin as 0.93 nmol/mg of 
membrane protein. Also, binding of bilirubin to membranes result in 
morphological alteration of erythrocytes (Brites et al., 1997). Loss of high 
affinity ouabain binding sites on the bilirubin-treated erythrocytes also suggests 
the presence of membranous bilirubin binding sites (Corchs et al., 1994). The 
characterization of the individual membrane components responsible for binding 
of bilirubin and the location of these sites, however, remains to be worked out. 
Biomembranes have two important constituents, i.e. lipids and proteins, and 
bilirubin binding sites are supposed to be made up of either lipids or proteins, or 
both. Involvement of membrane proteins as bilirubin binding sites has been ruled 
out in earlier studies (Sato & Kashiwamata, 1983; Chen et al., 1992) based on 
increase in bilirubin binding capacity after tryptic digestion and heat treatment of 
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Figure 4. Models proposed for the orientation/localization of bilirubin within 
the bilayer 
(i) Model proposed for the interaction of bilirubin with 
synaptosomal membrane (as given by Vazquez et al, 1988) 
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(ii) Internally hydrogen bonded structure of bilirubin IX a can have 
only three possible orientations in a lipid bilayer (as given by Zakim & 
Wong, 1990). 
(iii) Schematic representation of the proposed binding of amphipathic 
compounds that are crenators or cup-formers to the phospholipid regions 
of the erythrocyte membrane (Taken from Sheetz & Singer, 1974). 
(iv) Schematic illustration of experimental systems utilized for 
studying bilirubin transmembrane dififiision depicting that unconjugated 
bilirubin exhibits spontaneous diffusion through lipid bilayers and 
native hepatocyte membranes (Zucker et al, 1999). 
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membranes and failure in the afFmity labeling of any membrane proteins (Sato & 
Kashiwamata, 1983). It has been suggested that proteins may function as 
effective barrier to the binding of bilirubin. Contrarily, Leonard et al. (1989) 
have suggested that membrane proteins may exert some type of non-specific 
effect on the properties of the apolar phase of the bilayer, enhancing the capacity 
of the bilayer to sequester more bilirubin as compared to protein-free bilayer. 
However, it is widely accepted that membrane lipids and not proteins are the 
bilirubin binding sites. Vazquez et al. (1988) working on synaptosomal plasma 
membranes reported that bilirubin binding sites are mainly located on the outer 
layer of bilayer membrane. However, Karp et al. (1985) have suggested that 
bilirubin binds to both outer and inner surface of the membrane. This has also 
been supported by Sato et al. (1987) who showed no difference in bilirubin 
binding capacity of inside-out and right-side out sealed membranes. 
The mechanism of interaction of bilirubin with the lipid bilayer of erythrocyte 
membranes is still not clear. While Sheetz & Singer (1974) proposed that anionic 
or impermeable amphipathic compounds intercalate with lipids in the exterior 
half of the bilayer (Figure 4, iii) causing expansion of that bilayer relative to 
cytoplasmic half and induce crenation of cells, Nagaoka & Cowger (1978) have 
suggested that bilirubin is bound to the lipid bilayer through strong ionic 
interactions between a cationic head group of the lipid and anionic bilirubin. 
Binding constant has been reported to be highest for sphingomyelin as 3.7x10*' 
M'^  and diphosphatidylcholine with 5 % cholesterol as 2.6x 10^  M"*. Cestaro et al. 
(1983) have suggested that the dianion form of bilirubin binds weakly to polar 
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head groups of phospholipids whereas acid bilirubin binds strongly and is 
hydrophobically inserted into the lipophilic region of the bilayer. This 
hydrophibically bound bilirubin can perturb the chemico-physical properties such 
as fluidity, phase transition (Figure 5a) etc. of the membrane (Cestaro et al., 
1983). 
Binding of bilirubin to synaptosomal plasma membrane vesicles isolated from rat 
brain is suggested to occur in three steps (Vazquez el al., 1988) (Figure 4, i): 
(i) a rapid formation of an electrostatic complex between bilirubin and lipid polar 
head groups on the membrane surface, especially those from gangliosides and 
sphingomyelin; (ii) a slow inclusion of the pigment into hydrophobic core of the 
membrane and (iii) a membrane-mduced aggregation of bilirubin acid. 
The protruding ends of the lipids are supposed to be involved in the initial 
interaction with bilirubm (Vazquez et al., 1988) as treatment of membrane with 
phospholipases C and D resultes in a decrease and an increase in bilirubin 
association constant, respectively. However Sato el al. (1987) have found that 
phospholipase D treatment (which removes polar head groups of PC, PE and PS 
to foiTn phosphatidic acid as shown below) 
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does not change the bilirubin binding capacity of membranes whereas 
phospholipase C treatment enhances the bilirubin binding greatly. Therefore, the 
saturable bilirubin binding sites are probably located at positions on membranes 
that are not composed of polar head groups of phospholipids rather, the 
negatively charged phosphoric acid moiety of phospholipids prevents a large 
amount of bilirubin binding to the membranes. Leonard et al. (1989) are of the 
opinion that bilirubin interacts with neither the polar region nor the apolar 
regions of membranes but is localized within the membrane bilayer due to voids 
in the packing of bilayer. Zakim & Wong (1990) have reported that bilirubin is 
intercalated tightly into the polymethylene chain region in the bilayer (Figure 4, 
ii) whereas other views present the involvement of hydrogen bonding in bilirubin 
membrane interaction (Noy & Xu, 1990; Zucker et al, 1992). Further 
suggestions have been made that a major portion of bilirubin molecule is not 
localized within the hydrophobic domain of the bilayer but rather associated at 
the membrane surface and the dissociation of the membrane-bound bilirubin 
depends upon the phospholipid composition of the membranes and the 
membrane size (Zucker et ai, 1992; 1994). Recently, Brites et al. (1997) have 
suggested that bilirubin monovalent anion is the species first involved in the 
interaction with the erythrocyte membrane, the single ionized carboxyl group 
located in the aqueous medium, while the hydrophobic portion is buried in the 
bilayer, resembling a detergent. 
The influence of physico-chemical properties of the membranes such as 
overall charge on membrane surface, membrane fluidity (Figure 5a), pH and 
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Figure 5. (a) Phase transition in a lipid bilayer. 
(i) Above the transition temperature, both the Upid molecules as a whole and their 
nonpolar tails are highly mobile in the plane of the bilayer. 
(ii) Below the transition temperature, the lipid molecules form a much more orderly 
array to yield a gel-like solid. (Adapted from Voet, Voet & Pratt, 1998). 
(b) A model of the erythrocyte membrane. 
1. 100 000 mol. wt protein 2. Sialoglycoprotein 3. Spectrin 4.Glyceraldehyde-3-
phosphate dehydrogenase 5. (Na'^ -K )^-ATPase 6.Acetylcholinesterase. 
(Adapted from Juliano, 1973). 
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temperature on the binding of bilirubin to the membranes are of great concern. 
Vazquez et al. (1988) have suggested that the interaction of bilirubin with 
membrane is modulated by membrane fluidity such that lesser the fluidity, lesser 
the binding of bilirubin to membrane. Karp et al. (1985) are of the view that 
change in shape and size greatly affects the binding of bilirubin as seen by the 
expansion of erythrocyte membranes by a drug, chlorpromazine, which enhances 
bilirubin uptake of membranes by 45 %. Saturable binding of bilirubin to 
erythrocyte membranes has a pH optimum at around 7.1 (Sato & Kashiwamata, 
1983). A U-shaped thermal dependency of the total and saturable binding of 
bilirubin to erythrocyte membranes is reported with a minimum value near 37°C 
and gradual increase below and above this temperature (Sato & Kashiwamata, 
1983). Contrary to this, Leonard et al. (1989) have reported no such thermal 
dependency of the binding of bilirubin to biological membranes over a 
temperature range of 10-40°C. Addition of calcium chloride to the assay medium 
increases the binding of bilirubin to membrane (Sato et al, 1987; Vazquez et al, 
1988). In view of the binding of calcium to the sialic acid residues of membrane 
(Moore et al, 1984), Vazquez et al. (1988) have suggested that negative charges 
present on the sialic acid residues exert an inhibitory effect on the binding of 
bilirubin to membranes. Addition of calcium ions shields the negative charges of 
sialic acid residues, thereby increasing bilirubin binding. On the other hand, no 
significant change in bilirubin binding after neuraminadase treatment of 
membranes suggest that negative charges of sialic acid residues play little role in 
the binding of bilirubin to membrane. Recently, Brito et al (2000) have shown 
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that increased lipid fluidity and high bilirubin concentration promote membrane 
bilirubin translocation and toxicity. At low concentrations (nM), bilirubin prefers 
water-membrane interface, however, when concentration is increased to |iM 
range, it is situated in the inner core as well. Whether or not it diffuses across 
membrane bilayer needs more precise information. The temperature-dependent 
differences suggest that unconjugated bilirubin is differently located, or in a 
different physical state. However, albumin is not able to displace the bilirubin 
located deeply or aggregated within the membrane because of the conformational 
changes occuring by temperature in albumin (Brodersen, 1979) which increases 
the co-crystallization of unconjugated bilirubin and HSA. It has also been 
reported that antioxidant defence property of erythrocyte membrane is altered in 
jaundiced neonates (Mazumder et al., 1995). Studies in newborn humans have 
demonstrated alteration in the lipid, phospholipid and cholesterol content when 
compared with age-matched control. Membrane-bound (Na^-K^)ATP-ase activity 
is found to be significantly increased in jaundiced neonates. Alteration in 
membrane permeability characteristics in jaundiced neonates causes severe 
microenvironmental changes in ery^ocyte profile (Mazumder et al., 2Q{)Q)). 
ERYTHROCYTE MEMBRANE STRUCTURE 
It is generally agreed that the fluid mosaic model of membrane structure (Singer, 
1974) provides a satisfactory general description of the molecular organization of 
the proteins and lipids of most functional membranes (Figure 6a). In this model, 
the integral proteins are amphipathic molecules with their hydrophobic ends 
Anh^ni; 
Band 4.2 
Anion rhariiwl 
Figure 6. (a) Diagram of plasma membrane. Integral proteins 
are embedded in a bilayer composed of phospholipids and cholesterol. 
The carbohydrate components of glycoproteins and glycolipids occur only 
on the external face of the membrane. 
(b) A model of erythrocyte membrane skeleton, 
showing jmictional complex containing actin, tropomyosin and band 4.1 
protein as well as other proteins. 
(Adapted from Voet, Voet & Pratt, 1998). 
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embedded in the matrix of the membrane and their hydrophihc ends protruding 
from it. The matrix of the membrane is a bilayer of phospholipids, at least some 
part of which is fluid under physiological conditions. There is increasing 
evidence that both proteins and the phospholipids of membranes are 
asymmetrically distributed in the two halves of bilayer. 
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Asymmetrical distribution of phospholipids in human red blood cells 
expressed as mole percent (TPL, total phospholipid;PC, phosphatidyl 
choline;SM, sphingomyelin, PE, phosphatidyl ethanolamine; PS, 
phosphatidylserine and PI, phospliatidylinositol) 
(Adapted from Voet, Voet & Pratt, 1998) 
This evidence is most substantial for the erythrocyte membrane with respect to 
its proteins (Bretscher, 1973) and phospholipids (Zwaal et ai, 1973). 
Phosphatidylcholine (PC) and sphingomyelin (Sph)(choline-containing 
phospholipids) appear to be concentrated in the exterior half of the bilayer, and 
phosphatidylethanolamine (PE) and phosphatidylserine (PS)(amino 
phospholipids) in the cytoplasmic half (Bretscher, 1972; Op den Kamp, 1979). 
This typical transbilayer phospholipid asymmetry is disturbed in erythrocyte 
containing defective membrane skeleton (Williamson et al., 1982; Kumar & 
Gupta, 1983), Heating increases protein-protein association within the skeleton 
but membrane bilayer-skeleton interactions are not enhanced (Kumar et ai, 
1990). To survive in the circulation erythrocytes must be both durable and 
flexible, durable enough to withstand the turbulent cardiac passage and flexible 
enough to negotiate the narrow portals of the spleen. These dual demands are the 
responsibility of a sub membranous protein network functioning as membrane 
skeleton. Human erythrocyte membrane is composed of two stiTictural units, viz. 
membrane skeleton (or cytoskeleton) and membrane bilayer; of which the 
cytoskeleton is formed from three major (spectnn, actin and band 4.1) and 
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The major erythrocyte membrane polypeptides and glycoproteins 
several minor peripheral membrane proteins and is associated with the 
cytoplasmic face of the membrane bilayer through protein-protein and protein-
phospholipid interactions (Bennett, 1985). About 60 % of the membrane-protein 
mass comprises of membrane-skeleton including spectrin (bands 1 and 2), actin 
(band 5), ankyrin (bands 2.1, 2.2, 2.3 and 2.6) and band 4.1; and a portion of 
proteins designated bands 3, 4.2, 4.9 and 7. 
The membrane bilayer-skeleton association controls not only the membrane 
stability and deformability but also the lateral mobility of the integral membrane 
proteins (Sheetz et al, 1984). Besides, this association is considered to be a 
major factor in maintaining the asymmetric phospholipid distribution across the 
erythrocyte membrane bilayer (Haest, 1982). Membrane skeleton is shown to 
stabilize amino phospholipid distribution in the inner monolayer (Middelkoop et 
al, 1989) due to its interaction with phosphatidylserine (Shiffer et al, 1988; 
Rybicki et al, 1988). Also, membrane protein self-association is found to depend 
on the lipid composition of the membrane (Rothberg et al, 1990). Further, 
proteins like band 3 and Na^K'-ATPase are reported to be strongly associated 
with phospholipids (Rodgers & Glaser, 1993). Band 3 is the most abundant 
integral membrane protein and can perturb approximately 700 phospholipid 
molecules in a bilayer (Chicken & Sharon, 1984). The polypeptides of the 
erythrocyte membrane can be classified into two major groups (Figure 6, b): 
(i) extrinsic (peripheral) membrane proteins which are isolated from membrane 
by manipulation of ionic strength or pH (the peptides corresponding to bands 
1,2,4,5 and 6). Moreover, two kinds of this membrane proteins are: (a) tightly 
bound- not eluted with physiologic saline in vitro such as ankyrin (band 2.1) 
which also binds to spectrin and links the submembrane skeleton to the 
membrane and band 4.2 and (b) loosely bound- readily eluted with physiologic 
saline in vitro such as glycolytic enzymes (phosphofructokinase, aldolase and 
glyceraldehyde-3-phosphate-dehydrogenase). 
(ii) intrinsic (integral) membrane proteins: requires detergents or strong 
chaotropic agents for their separation as they are more intimately bound (bands 3, 
7andPAS-l,2, 3and4). 
Circular dichroism (CD) studies of membranes revealed that the portions of 
erythrocyte membrane proteins that are embedded in the lipid bilayer contain a 
very high (86-94 %) content of a-helix (Oikawa et ai, 1985). Recently, CD has 
been widely used for studying the conformation and conformational change of 
proteins and polypeptides in solution. The use of phospholipases has turned out 
to be a valuable tool for investigation of the function of membrane phospholipids 
and their distribution in the membrane structure (Op den Kamp, 1979), mostly 
human erythrocyte membrane bilayer (Witt & Gercken, 1986). Membrane 
permeation of small molecules is the basis of passive drug and metabolite uptake. 
In order to traverse a lipid bilayer membrane, a solute must enter through the 
polar head group region diffuse within the hydrocarbon region and 
then leave 
through the polar head group region on the other side (Bassolino-Klimas etal., 
1993). The development of new drug delivery systems has taken advantage of the 
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physiological nature of the erythrocytes to use these cells as carriers (Tonetti and 
Flora, 1993). 
DRUG-INDUCED BILIRUBIN DISPLACEMENT FROM ALBUMIN 
AND ITS EFFECT ON ER YTIIROCYTES 
The transfer of bilirubin from plasma to cells depends on the ratio of 
unconjugated plasma biliiubin concentration to the concentration of resei-ve 
albumin and is increased when part of the albumin is either occupied by 
competitive binding of a drug or unable to bind bilirubin such as at low pH 
values. 
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Proposed mechanism of drug-induced bilirubin transfer from plasma to 
nerve cell (Brodersen et aL, 1983) and partition of unconjugated 
bilirubin in the blood 
Silverman et al. (1956) have reported increased frequency of kemicterus after 
administration of combination of sufisoxazole and penicillin. Odell (1959) has 
explained this as a result of displacement of bilirubin from binding to serum 
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albumin. Lee & Cowger (1974) have believed that displacement of bilirubin 
bound to the secondary sites on albumin is more likely than displacement from 
the primary high affinity site. Some drugs are tightly bound to serum albumin in 
the blood and some are bound to a lesser degree. The concentration of the drug 
must be larger than 15 \iM to cause significant bilirubin binding competition and 
based on the chemical nature, most displacing drugs are anionic or without a net 
electric charge but none of the displacers are lipophilic (Robertson e( ai, 1991). 
A displacement constant (KQ) has been calculated by Robertson and his 
associates (Robertson et ai, 1991) which represents the competitive effect of the 
drug with bilirubin for albumin binding. A maximal displacement factor, 5 is 
calculated from KD value using the following equation: 
5 = KD d + 1 
where 'd' is the concentration of free drug in patients' plasma. If d=l or KD=0 
means "no displacement" and if d=1.2, it means that 20 % increase of free 
bilirubin concentration. Brodersen (1978) suggested that d=1.2 could be taken as 
an upper limit for permissible degrees of bilirubin displacement. The maximal 
displacement factor (5) for ceftriaxone and sodium salicylate has been given as 
3.00 and 1.5 and their KD values as 1.5x10" L/mol and 0.92x10^ L/mol, 
respectively (Brodersen, 1978). Binding of bilirubin to erythrocytes in a mixture 
of bilirubin, albimiin and drug has been used as a method for studying the 
bilirubin displacing action of drugs (Bratlid, 1973). The three steps involved in 
the displacement mechanism are the dissociation of bilirubin from bilinibin-
albumin complex; transfer of bilirubin from blood plasma to nerve cells and 
failure of intracellular bilirubin disposition by oxidases. Drugs could influence all 
the three steps and the whole mechanism of drug-induced kemicterus may thus, 
seem to be quite complex. According to Gulian et al. (1986), three forms of 
bilirubin are present in blood vessels of hyperbilirubinemic neonates; (1) major 
part of bilirubin is bound to serum albumin (2) linked to erythrocyte lipid 
membrane and (3) unbound bilirubin, which is the free soluble form. All the 
three forms are in equilibrium with each other. Displacement of bilirubin to brain 
requires the opening of blood-brain barrier. 
The uptake of bilirubin by human erythrocyte ghosts occurs in the presence of 
several drugs used clinically in neonates and distinction has been made between 
effects caused by drug-albumin-bilirubin interactions, ghost lysis, and direct 
action of the drug on the erythrocyte membrane. A drug may displace bilirubin 
from albumin (Brodersen, 1978), cause nonhemolytic membrane changes, such 
as membrane expansion (Kwant & Seeman, 1969) or endocytosis (Schrier & 
Junga, 1981) or hemolyze the erythrocyte (Seeman, 1966). Drug binding to 
erythrocytes is of significance in understanding their distribution and other 
pharmacokinetic parameters. Bilipid membrane of erythrocytes is perforated with 
pores of various diameter which act as aqueous channels. Drugs can enter cells 
either by passing through bilipid membrane or through aqueous channels. A 
positive correlation between partition coefficient and binding suggests that 
salicylates enter cells through bilipid membrane and not through aqueous 
channels (Rao & Kumar, 1985). Also, study performed on blood samples from 
icteric neonates, showed that the addition of ceftriaxone produced an increase in 
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free bilirubin and erythrocyte-bound bilirubin and a decrease in unconjugated 
bilirubin (Guliane/a/., 1987). 
A brief review of literature suggests that these studies are limited in the data 
on the behavior of bilirubin binding to membranes at various B/As (which are 
known to exist under physiological and jaundiced conditions) and at different pH 
and temperatures. In this study, the effect of pH and temperature on the binding 
of bilirubin to human erythrocyte membranes at different B/As has been 
reinvestigated since most of the earlier studies on the binding of bilirubin to 
membranes were carried out either in albumin-free medium (Cestaro et al, 1983) 
or at a constant B/A i.e., 2.0 (Sato & Kashiwamata, 1983; Sato et al, 1987; 
Vazquez et al, 1988). From the above review on the bilirubin binding to 
erythrocyte membranes/biological membranes, it also appears that more studies 
are required to confirm the localization of bilirubin in the erythrocyte membranes 
in terms of surface binding, internal binding, hydrophobic binding etc. Therefore, 
we have also studied the interaction of bilirubin with different types of 
erythrocyte membrane vesicles such as unsealed, heterogeneous, sealed and 
inside-out vesicles of two mammalian species namely, human and goat. Further, 
the effect of phospholipases C and D, trypsin, neuraminidase and Ca^ ^ on the 
mode of binding of bilirubin to erythrocyte membranes has been studied in detail. 
Attempts have also been made towards identifying the role of membrane proteins 
in bilirubin binding phenomenon after the removal of membrane proteins with 
specific reagents and studying the interaction of these protein-depleted 
membranes with bilirubin. Visible CD spectroscopy has also been employed 
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towards the study of interaction of bilirubin with sealed and HSA-entrapped 
sealed membranes. 
c 
cr 
Methods 
MATERIALS AND METHODS 
[A] MATERIALS 
1. Proteins 
Bovine serum albumin, fraction V (lot 100F0249), neuraminidase, type V from 
Clostrium perfringens (lot 31H82302), phenylmethylsulfonylfluoride, PMSF (lot 
67H1645), phospholipase C, type XIV from Clostridium welchii (lot 55H6334), 
phospholipase D, type I from cabbage (lot 57H0373) and trypsin, TPCK-treated 
from bovine pancreas (lot 117H7261) were purchased from Sigma Chemical 
Company, MO, USA. Human and goat serum albumins were isolated from their 
respective plasma by ammonium sulfate fractionation method (Tayyab & Qasim, 
1990). 
2. Reagents used in protein estimation 
Analytical grade samples of copper sulfate, hydrochloric acid, lithium sulfate, 
orthophosphoric acid, sodium carbonate, sodium molybdate, sodium potassium 
tartarate and sodium tungstate were obtained from Qualigens Fine Chemicals, 
Mumbai, India. Liquid bromine was procured from Sigma Chemical Company, 
MO, U.S.A. Folin-phenol reagent was prepared according to the standard 
procedure (Folin & Ciocalteu, 1927). Copper reagent was prepared fresh by 
mixing 1 volume of 4 % (w/v) sodium potassium tartarate to 100 volumes of 4 % 
(w/v) sodium carbonate and finally adding 1 volume of 2 % (w/v) copper sulfate. 
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3. Reagents used in membrane modification 
Dimethylmaleic anhydride (lot 77H252]), 3,5-diiodosalicylic acid, lithium salt 
(lot 48H0714), 2-mercaptoethanol (lot 53H074]) and 1,10-phenanthroline (lot 
77H0316) were purchased from Sigma Chemical Company, MO, USA. Copper 
sulfate (AR), disodium salt (AR) and ethylenediaminetetra acetic acid (AR) were 
supplied by Qualigens Fine Chemicals, Mumbai, India. Sodium iodide (LR) was 
the product of Loba Chemie, Mumbai, India. 
4. Reagents used in bilirubin estimation 
Bilirubin (GR), caffeine anhydrous (LR), sulfanilic acid (LR), sodium benzoate 
(GR) and sodium nitrite (AR) were the products of S.D. Fine Chemicals, Boisar, 
India. Sodium acetate (AR) and sodium hydroxide (GPR) were obtained from 
Qualigens Fine Chemicals, Mumbai, India. 
5. Reagents used in gel electrophoresis 
Acrylamide (3x crystallized, LR) and N, N'-methylenebisacrylamide (3x 
crystallized, AR) were purchased from Sisco Research Laboratories, Mumbai, 
India. Coomassie brilliant blue, R 250 (type B-7920), glycine, LR (lot 
113H12551) and trizma base (tris [hydroxymethyl] aminomethane, AR) (lot 
14H5717) were obtained from Sigma Chemical Company, MO, U.S.A. 
Analytical grade samples of ammonium persulfate, acetic acid, glycerol, 
methanol and sucrose were procured from Qualigens Fine Chemicals, Mumbai, 
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India. N, N, N', N'-tetramethylethylenediamine (TEMED) was the product of 
Fluka, AG, Switzerland. Bromophenol blue was obtained from B.D.H., Poole, 
England. Carbocyanine dye. Stains-all (SA-1) was the product of Eastman Fine 
Chemicals, New York, U.S.A (No. 2718) and formaraide, extrapure AR was 
obtained from Sisco Reasearcli Laboratories, Mumbai, India. 
6. Reagents used in inorganic phosphorus estimation 
(a) Fiske & Subbarow (1925) method: L-Ascorbic acid (AR) was obtained 
from Sisco Reasearch Laboratories, Mumbai, India. Ammonium 
molybdate (LR), perchloric acid (LR) and sodium dihydrogen 
orthophosphate (AR) were the products of Qualigens Fine Chemicals, 
Mumbai, India. 
(b) Ames & Dubin (1960) method: Magnesium nitrate (LR) and sulfijric 
acid (LR) were the products of Qualigens Fine Chemicals, Mumbai, India. 
Ethanol absolute (GR) was obtained from E.Merck, Darmstadt, Gennany. 
7. Reagents used in thin-layer chromatography (TLC) 
Acetone, extrapure (AR), benzene, extrapure (AR), chloroform (AR) and 
isopropyl alcohol, extrapure (AR) were purchased from Sisco Research 
Laboratories, Mumbai, India. Liquor ammonia solution (AR) and iodine (LR) 
were the products of Qualigens Fine Chemicals, Mumbai, India. 
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8. Reagents used in sialic acid estimation 
Thiobarbituric acid (GPR) was purchased from B.D.H., Poole, England. N-acetyl 
neuraminic acid, type IV-S (lot 33H78141) was obtained from Sigma Chemical 
Company, MO, U.S.A. Ammonium periodate (AR) and sodium sulfate (LR) 
were the products of Qualigens Fine Chemicals, Mumbai, India. Sodium arsenite 
(GR) was purchased from Loba Chemie, Mumbai, India. 
9. Reagents used in carbohydrate estimation 
Orcinol (extrapure) was supplied by Sisco Research Laboratories, Mumbai, 
India. Dextrose (LR) and sucrose (LR) were obtained from Qualigens Fine 
Chemicals. Mumbai, India. 
10. Reagents used in choline estimation 
Ammonium reineckate and choline chloride, extrapure were purchased from 
Loba Chemie, Mumbai, India. Phenophthalein was obtained from Qualigens Fine 
Chemicals, Mumbai, India. n-Propanol was the product of Sisco Research 
Laboratories, Mumbai, India. 
11. Drugs 
Ceftriaxone (lot 82H0034) was obtained from Sigma Chemical Company, MO, 
U.S.A. Sodium salicylate (AR) was purchased from Central Drug House, New 
Delhi, India. 
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12. Miscellaneous 
Ammonium sulfate (LR), calcium chloride (LR), di-sodium hydrogen phosphate 
(LR), potassium hydrogen phthalate (LR), sodium chloride (AR), sodium 
dodecyl sulfate (LR), sodium dihydrogen phosphate (LR) and sodium tetraborate 
(LR) were obtained from QuaHgens Fine Chemicals, Mumbai, India. Magnesium 
sulfate was the product of E.Merck, Mumbai, India and tii-sodium citrate (LR) 
was procured from B.D.H., Mumbai, India. 
Fresh human blood (B-Rh+ve) was collected from donors while outdated 
human blood in 1.32% sodium citrate and 1.47% dextrose was supplied by the 
Blood Bank of Jawaharlal Nehru Medical College, Aligarh Muslim University, 
Aligarh. Goat blood was collected from the local slaughterhouse in 1.32% 
sodium citrate. 
Silica impregnated aluminium sheets (20x20 cm, silica gel 60F254) were from 
E.Merck, Darmstadt, Germany. Dialysis membrane tubing of linch width was 
obtained from Sigma Chemical Company, MO, U.S.A. Millipore filters (pore 
size 0.45 ^m) were purchased from Millipore (India) Pvt. Ltd., Bangalore, India. 
Whatman filter papers (No. 1) were the product of Whatman International Ltd., 
Maidstone, England. Parafilm 'M' was obtained from American Can Company, 
CT, U.S.A. pH indicator papers were supplied by Qualigens Fine Chemicals, 
Mumbai, India. 
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All glass-distilled water was used throughout these studies. All the 
experiments were performed at room temperature (~25°C) unless otherwise 
stated. 
AR= Analytical Reagent GR= Guaranteed Reagent 
LR= Laboratory Reagent GPR=General Purpose Reagent 
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[B] METHODS 
1. pH measurements 
pH measurements were carried out on an Elico digital pH meter, model LI 610 
using a combined electrode, type CL-51. The least count of the pH meter was 
0.0 IpH unit. The pH meter was routinely calibrated at room temperature with 
either 0.05 M potassium hydrogen phthalate buffer, pH 4.0 in the acidic range or 
0.01 M sodium tetraborate buffer, pH 9.2 in the alkaline range. 
2. Optical measurements 
Cecil double beam spectrophotometer, model CE594 was used for light 
absorption measurements in the ultraviolet (UV) as well as visible regions using 
quartz and glass cuvettes, xespectively. Absorption measurements in the visible 
range were also made on AIMIL Photochem-8 colorimeter, using glass cuvettes 
of I cm pathlength. 
3. Determination of protein concentration 
Protein -concentration was determined either spectrophotometrically or by the 
method of Lowry etxil. (1951) using bo\Tne serum albumin as the standard, 
(a) Spectrophotometric method: Protein concentration was determined 
following absorbance measurement at 279 nm using the value of specific 
extinction coefficient (E^ "'^  icm) as 6.67 and 5.31 for bovine serum albumin and 
human serum albumin, respectively (Peters, 1985). 
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(b) Method of Lown et al (1951): Increasing volumes (0.1-1.0 ml) of stock 
protein solution (0.5 mg/ml) were taken in series of tubes and tlie volume in each 
tube was made to 1.0 ml if required, with 0.07 M sodium phosphate buffer, pH 
7.4 containing 0.08 M NaCl. Then, 5.0 ml of freshly prepared copper reagent was 
added to all the tubes and the contents were mixed well. After 10 muiutes of 
incubation at room temperature, 1.0 ml of diluted Folm-phenol reagent was 
added and vortexed. The tubes were then incubated for 30 minutes at room 
temperature and the color intensity was read at 700 mii against a suitable blank 
prepared in the same way as that of test solution except that instead of protein 
solution, 1.0 ml of buffer was taken. A calibration curve, thus obtained, between 
absorbance at 700 nm and amount of protein (mg) yielded the following straight 
line equation (Fig.7): 
(Absorbance)7oo nm - 5 72 (amount of protein, mg) + 0.087 (1) 
Protein measurements were also perfomied m 50 niM tiis-HCl buffer, pH 7.4 
as well as 10 niiVI tns-HCl buffer, pH 7.4 containmg 1% SDS. The above 
protocol was employed to obtam other stiaigiit Ime equations for protein in 50 
nuVI tris-HCl buffer, pH 7.4 and 10 mM tris-HCl buffer, pH 7.4 contauiing 1% 
(w/v) SDS, respectively (Fig.7); 
(Absorbance)7oo nm = 1 • 13 (amount of protein, mg) + 0.003 (2) 
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Figure 7. Standard curves for the determination of protein 
concentration by the method of Lowry et al. (1951) obtained with 
0.07 M sodium phosphate buffer, pH 7.4 containing 0.08 M NaCl 
( O ), 50 mM tris-HCl buffer, pH 7.4 ( • ) and 10 mM tris-HCl 
buffer, pH 7.4 containing 1% (w/v) SDS ( A ). 
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(Absorbance)7oo nm= 111 (amount of protein, mg) + (-0.005) (3) 
For the estimation of erythrocyte membrane proteins by the method of Lowry 
et al. (1951), membranes were subjected to solubilization in 1% (w/v) SDS. To 
0.1 ml of erythrocyte membrane suspension in 50 mM tris-HCl buffer, pH 7.4 
was added 0.9 ml of 1.1% (w/v) SDS and incubated at 60°C for 30 minutes. 
After complete solubilization of membranes, the above protocol was followed 
and protein concentration was determined using equation (3). 
4. Isolation of seruni albumin 
Serum albumin was isolated from human/goat blood according to the method 
described by Tayyab & Qasim (1990). Blood was centrifuged at 1500xg for 20 
minutes to obtain plasma, which was brought to 2.26 M in ammoniimi sulfate by 
adding requisite volume of 4 M ammonium sulfate solution, pH 7.0. The mixture 
was kept for 12 hours at room temperature and then carefully diluted with water 
and with fiequent additions of 0.5 N H2SO4 such that the final concentration of 
ammonium sulfate was reduced to 1.9 M and the pH to 4.2. After incubating it 
for 12 hours at room temperature, the precipitate was collected by centrifiigation 
at 3000xg for 30 minutes. It was washed three times with 2.2 M ammonium 
sulfate solution, pH 4.2 and then dissolved in 0.07 M sodium phosphate buffer, 
pH 7.4 containing 0.08 M NaCl. The protein preparation, thus obtained, was 
extensively dialyzed against 6 litres of the desired buffer, either 0.07 M sodium 
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phosphate buffer, pH 7.4 containing 0.08 M NaCl or 50 mM tris-HCl buffer, pH 
7.4 and stored at 4°C. 
5. Polyacrylamide gel electrophoresis (PAGE) 
Electrophoresis of human serum albumin and goat serum albumin was performed 
in 8 % (w/v) polyacrylamide gel while electrophoresis of human erythrocyte 
membrane and its treated derivatives was performed in 10% (w/v) 
polyacrylamide gels, using 0.02 M tris-glycine buffer, pH 8.2, ionic strength 0.02 
following the method of Laemmli (1970) under non-denaturing and denaturing 
conditions, respectively. Upto 5-8 |ig for serum albumins and 50 [xg of protein 
for erythrocyte membrane and their derivatives was applied in 20 jil of sample 
buffer, and a current of 3-4 mA per well was passed for nearly 2 hours. 
(a) The gels were stained with a staining solution containing 0.25% (w/v) 
coomassie brillicmt blue in 40% (v/v) methanol and 10% (v/v) acetic acid and 
destamed with 10% (v/v) acetic acid solution containing 10% (v/v) methanol at 
37°C. 
(b) Fixing and staining with carbocyanine was performed by the method 
followed by King et al. (1976). The gels were fixed in 10-20 ml of 10-25% 
isopropanol and then washed exhaustively in 25% isopropanol for 18-36 hours 
with fi"equent changes or heated to 56°C for 1-2 hours to remove SDS. Staining 
method of Green et al. (1973) was employed where 5.0 ml of stock solution of 
carbocyanine (0.1% w/v in formamide) was diluted with 20 ml formamide, 100 
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ml isopropanol and 275 ml of 15 mM tris to give 400 ml. The pH was adjusted to 
8.5 with NaOH or HCl. The gels were placed in 10-20 ml of working stain 
solution overnight in dark. The gels were destained in 10-20 ml of 10% 
isopropanol for 18-36 hours at 25°C, 
In crosslinking experiments, unreduced membrane samples were prepared in 
the same way as described above but in the absence of 2-mercaptoethanol. The 
gels were stained for proteins with coomassie blue. 
6. Determination of bilirubin concentration 
Bilirubin concentration was determined by modified Jendrassik & Grof method 
(1938) [Fog's method (1958)] as "alkaline a^obilirubin". The method involved 
the use of three reagents namely, I, II and III which were prepared in the 
following manner: 
(i) Preparation of reagent I : Twenty grams of caffeine anhydrous, 30 gms 
of sodium benzoate and 50 gms of sodium acetate were dissolved in 400 ml of 
water and the mixture was warmed up to 50°C with continuous stirring until a 
clear transparent solution was obtained. 
(ii) Preparation of reagent II : Working solution of reagent II was prepared 
fresh just before the experiment by adding 3 drops of reagent lib (containing 500 
mg of sodium nitrite in 100 ml of water) in 5.0 ml of reagent Ha (prepared by 
dissolving 0.5 gm of sulfanilic acid in 1.5 ml of concentrated hydrochloric acid 
followed by dilution with 100 ml of water). 
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(iii) Preparation of reagent III : Thirty grams of sodium hydroxide was 
dissolved along with 105 gm of sodium potassium tartarate in 300 ml of water. 
Preparation of stock bilirubin solution 
Stock solution of bilirubin was prepared by dissolving few crystals of bilirubin in 
IN NaOH, containing 5 mM EDTA and diluting it to 10 ml with 0.06 M sodium 
phosphate buffer, pH 8.0. The concentration of bilirubin was determined 
spectrophotometrically using a molar absorption coefficient of 47,500 M'^ cm"' at 
440 nm (Jacobsen & Wennberg, 1974). Bilirubin solution was stored in dark. All 
the spectral measurements were recorded in dim/yellow light to prevent 
undesired photodegradation of bilirubin and the bilirubin solution was used 
within an hour of preparation. 
Procedure: Increasing volumes (0.1-1.0 ml) of stock bilirubin solution (90 p.M) 
were added to different tubes and the final volume was made to 1.0 ml, if 
required, with buffer. This was followed by the addition of 2.0 ml of reagent I 
and 0.5 ml of reagent II, with gentle mixing. After 10 minutes of incubation at 
room temperature, 1.5 ml of reagent III was added to all the tubes and the 
contents were mixed well. Absorbance of the solution was read at 600 nm against 
buffer. For each bilirubin concentration, reagent II blank and bilirubin blank were 
prepared in the same way as described above except that buffer was used instead 
of reagent II and bilirubin in these blanks, respectively. Absorbance of diazotised 
bilirubin solution was determined by subtracting the absorbance values of 
reagent 11 blank and bilirubin blank from the absorbance of bilirubin solution. 
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Data were plotted as absorbance at 600 nm versus bilirubin concentration, which 
yielded the following straight line equation (Fig.8): 
(Absorbance)6oonm='0.015 (amount of bilirubin, nmoles) + (-0.0064) (4) 
Presence of either serum albumin or 1% (w/v) SDS in the bilirubin stock 
solution and the use of 38 mM sodium carbonate solution containing 5 mM 
EDTA, pH 11.0 instead of 0.06 M sodium phosphate buffer, pH 8.0 did not affect 
the value of slope of the standard curve (Fig.8). In SDS containing samples, 
turbidity caused by SDS was removed by centrifugation at 16,000xg for 20 
minutes. 
For experiments involving metal ions, EDTA was eliminated from the 
solutions. Therefore, bilirubin solution was prepared in 38 mM sodium carbonate 
solution, pH 11.0. A calibration curve in the presence of CaCl2 (1,2 and 3 mM) 
was also plotted in the same way as above (Fig.8). The increasing concentration 
of CaCli did not change the slope of the calibration curve. In the presence of 
metal ions, the straight line relationship is: 
(Absorbance)6oonin= 0.012 (amount of bilirubin, nmoles) + (-0.0146) (5) 
7. Inorganic phosphorus estimation 
(a) Inorganic phosphorus was determined by the method of Fiske & 
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concentration by Fog's method (1958) obtained with 1 N sodium 
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Subbarow (1925). Different volumes of stock solution, prepared by dissolving 
16.67 mg of di-sodium hydrogen phosphate in 100 ml of water (equivalent to 
37.6 )j,g of inorganic phosphorus per ml of this solution), were taken in the range 
of 0.1-1.0 ml in different tubes and the volume in each tube was adjusted to 5.0 
ml with water. Then 0.2 ml of 5% (w/v) ammonium molybdate was added to all 
the tubes and mixed well. It was followed by the addition of 0.2 ml of 0.1% (w/v) 
ascorbic acid. The contents were mixed well and the tubes were incubated at 
80°C for 30 minutes, then cooled under tap water and the absorbance was read at 
700 nm against an appropriate blank. Data were plotted as absorbance at 700 nm 
versus amount of inorganic phosphorus, which yielded the following straight line 
equation (Fig. 9): 
(Absorbance)7oonm= 0.025 (amount of inorganic phosphorus, \xg) + 0.029 (6) 
(b) Inorganic phosphorus measurement was also performed by the method of 
Ames & Dubin (1960). Increasing volumes of stock solution prepared by 
dissolving 5 mg of di-sodium hydrogen phosphate in 5 ml of water (equivalent to 
225 jig of inorganic phosphorus per ml of this solution), were taken in the range 
of 5-50 |il in different tubes and 0.18 ml of 10% magnesium nitrate dissolved in 
absolute alcohol was added to each tube. Each of these tubes was ignited to get 
white ash and then 1.8 ml of 0.5 N HCl was added to all tubes. The contents were 
mixed well with a vortex and heated in a boiling water bath for 15 minutes for 
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complete digestion. The tubes were cooled under tap water and 4.2 ml of 
ammonium molybdate-ascorbic acid solution (6:1), prepared fresh, was added to 
all the tubes. Absorbance was read at 820 nm. Data were plotted as absorbance at 
820 nm versus amount of inorganic phosphorus, which yielded the following 
straight line equation (Fig. 9): 
(Absorbance)820nm= 0.034 (amount of inorganic phosphorus, )ig) + 0.013 (7) 
For the determination of total inorganic phosphorus of erythrocyte membranes, 
initially the organic matter was destroyed by heating the membranes (0.2 ml 
suspension in 50 mM tris-HCl buffer, pH 7.4) at 180°C for 2 hours with 1.0 ml of 
70% (v/v) perchloric acid and then adjusting the volume to 1.0 ml with water. 
The inorganic phosphorus was determined in the same way as described above 
using equation (6). 
8. Sialic acid estimation 
Thiobarbituric acid assay, given by Warren (1959) was employed for the 
determination of sialic acid content using N-acetyhieuraminic acid as the 
standard. The follo\^ing reagents were used in this assay: 
(a) 0.2 M sodium meta-periodate in 9 M orthophosphoric acid 
(b) 10% (w/v) sodium arsenite in a solution of 0.5 M sodium sulfate and O.IN 
sulfuric acid 
59 
(c) 0.6% (w/v) thiobarbituric acid in a solution of 0.5 M sodium sulfate. 
All the above solutions were stored at room temperature and used within a 
month. 
Procedure: To a volume ranging from 20-200 fxl of stock solution, prepared by 
dissolving 3.8 mg of N-acetylneuraminic acid in 50 ml of water (equivalent to 
0.25 p,mole of N-acetylneuraminic acid per ml of this solution), was added water, 
if required, to make up the volume to 0.2 ml. Then 0.1 ml of periodate solution 
was added. After mixing, the contents were kept at room temperature for 20 
minutes. One ml of arsenite solution was added to all the tubes and the contents 
were shaken well until a yellow color, first formed, disappeared. Then, 3.0 ml of 
thiobarbituric acid reagent was added and the tubes were heated at 100°C for 15 
minutes by keeping them in vigorously boiling water bath. The tubes were then 
cooled under tap water and the entire solution was added to an equal volume of 
cyclohexanone. The tubes were shaken well and centrifiiged at 1500xg for 5 
minutes. The upper pink layer was aspirated with Pasteur pipette and the 
absorbance was read at 550 run against the blank prepared in the same way but 
without N-acetylneuraminic acid. The data were plotted as absorbance at 550 nm 
versus |j,moles of N-acetykieuraminic acid (NANA) (Fig. 10), which yielded the 
following straight line equation: 
(Absorbance)550nin= 12.72 (amount of N-acetylneuraminic acid, |imoles) + 0.016 (8) 
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For the determination of sialic acid content of erythrocyte membranes, sialic 
acid was liberated from membranes by mild acid hydrolysis in O.IN sulfuric acid 
at 80°C for 1 hour. Then, the solution was cooled to room temperature, 
centrifiiged at 16,000xg for 20 minutes and sialic acid content was determined in 
the same way as described above using equation (8). 
9. Carbohydrate estimation 
Orcinol method was employed for the determination of carbohydrate 
concentration using glucose (0.2 mg/ml) as the standard (Svermerholm, 1956). 
To 1.0 ml of solution containing 20-200 |.ig glucose was added 200 |il of orcinol 
reagent (prepared by dissolving 150 mg orcinol in TO ml of 30% (v/v) sulfuric 
acid) followed by the addition of 2.5 ml of 60% (v/v) sulfuric acid. The contents 
were rapidly mixed and incubated at 80°C for 20 minutes. The tubes were then 
cooled and left for 45 minutes in the dark. The absorbance was read at 470 nm 
against a blank prepared I the same way but substituting water for sugar solution. 
The data, thus obtained, were plotted as absorbance at 470 nm versus the amount 
of glucose (mg) which yielded the following straight line equation (Fig.l 1): 
(Absorbance)470mn= 3.67 (amount of glucose, mg) + 0.018 (9) 
The carbohydrate content of erythrocyte membranes was determined in the 
same way by subjecting the erythrocyte membranes directly to the orcinol 
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reaction. 
10. Choline estimation 
The choline content was determined following the procedure of Kates & Sastry 
(1969). Varying volumes of stock choline chloride solution (1.15 g/litre) ranging 
from 4-20 juimoles of choline in a volume of 3.0 ml were taken in a graduated 15 
ml centriflige tube and a few drops of phenolphthalein solution (1% in ethanol-
water in 1:1, v/v) were added. The solution was made alkaline by the addition of 
2N NaOH and diluted with water to 5 ml. To this, 2.5 ml of ammonium 
reineckate solution (2% in methanol) was added and the contents were swirled in 
a vortex mixer and kept at 5°C for 2 hours. 
Pink precipitate of choline reineckate is spun down in a centrifuge at 16,000xg 
for 20 minutes, washed twice with 1.0 ml portions of n-propanol and then 
dissolved in 5.0 ml of acetone, centrifiiged, decanted and read at 526 nm against 
a blank where choline chloride was substituted with water. The data, thus 
obtained, were plotted as absorbance at 526 nm against the amount of choline 
yielding the following straight line equation (Fig. 12): 
(Absorbance)526nm= 0.18 (amount of choline, iimoles) + 0.031 (10) 
11. Preparation of erythrocyte suspension 
Human/goat erythrocytes were collected by centrifugation of blood at lOOOxg for 
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20 minutes at 4°C. Plasma and "buffy coat" were removed by careful aspiration 
and cells were then resuspended in 50 mM tris-HCl buffer, pH 7.4 containing 
100 mM NaCl or 50 mM sodium phosphate buffer, pH 7.4/8.0 containing 150 
mM NaCl followed by triple washing with the same buffer. After each step of 
centrifugation, the surface of the pellet was thoroughly aspirated. The packed 
washed cells were diluted with an equal volume of the same buffer to obtain 50% 
hematocrit value. 
12. Preparation of erythrocyte membrane suspension 
Erythrocyte membranes were prepared in the same way as described by Palfrey 
& Waseem (1985). Erythrocyte suspension of 50% hematocrit value was 
hemolysed with 10 volumes of cold 10 mM tris-HCl buffer, pH 7.4 containing 
0.01 mM EDTA and 0.01 mM PMSF followed by gentle swirling and 
centrifugation at 16,000xg for 20 minutes at 4°C. The dark red supernatant was 
removed carefully by gentle aspiration. Each tube was tilted and rotated to allow 
the loose ghost pellet to slide off to another tube, leaving the tightly packed 
"buttons" at the bottom of the tube. This minimized the contamination of the 
ghost with proteinases as suggested by Fairbanks et al (1971). The ghost pellet, 
thus obtained, was washed several times with the same buffer followed by 
centrifugation at 16,000xg for 20 minutes at 4°C until membranes were free from 
hemoglobin. After final washing, the erythrocyte membrane pellet was 
resuspended in the same hemolysing buffer such that the total volume of 
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membrane suspension was equal to the volume of erythrocyte suspension of 50% 
hematocrit value initially taken for hemolysis. This suspension was stored at 
10°C and washed once with 50 mM tris-HCl buffer, pH 7.4 prior to use and the 
volume was restored to the initial volume taken with the same buffer. However, 
erythrocyte membrane suspension stored in 10 mM tris-HCl buffer, pH 7.4 could 
be used within five days when kept at 10°C. 
Density separation of erythrocytes into different age groups was based on the 
method of Murphy (1973). Fresh blood from donor (B-Rh+ve) was centrifliged 
in graduated centrifiige tubes at lOOOxg for 10 minutes at 30°C, the plasma was 
retained and the "buffy coat" was discarded carefully avoiding loss of 
erythrocytes. The cells were then washed by adding back their own plasma and 
recentrifuged as above. The plasma and "buffy coat" were again discarded 
carefully. The erythrocytes, which were at about 90 % hematocrit, then were 
spun at 30,000xg for 1 hour at 30°C. Any excess plasma and buffy coat were 
removed and discarded taking care of loss of erythrocytes. Fractions of the cells 
were collected by volume from the top to the bottom of the tube representing the 
top 10 %, two middle fractions of 40 % each, and the bottom 10 %. These four 
fractions were young (top), intermediate (two middle) and old (bottom) 
erythrocytes, respectively. These fractions were washed with 50 mM tris-HCl 
buffer, pH 7.4 containing 150 mM NaCl and were then hemolysed using the 
same hemolysing buffer as that used for the preparation of erythrocyte 
membranes described earlier. 
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Different procedures were adapted for using these membranes in different 
experiments. 
(a) For experiments involving the effect of pH and temperature on human 
erythrocyte membranes, the prepared erythrocyte membrane suspension was 
divided into aliquots, washing each of them with respective 50 mM tris-HCl 
buffer of different pH i.e., 7.8, 7.6, 7.4, 7.2, 7.0 and mixed with a volume of 
buffer equivalent to the volume of the aliquot taken initially. 
(b) Different membrane vesicles such as sealed, heterogeneous and inside-out 
vesicles were prepared from the unsealed membrane vesicles following the 
method of Steck & Kant (1973) with little modification. 
Unsealed erythrocyte membranes were obtained after hemolysing erythrocyte 
suspension of 50% hematocrit value with 5 mM sodium phosphate buffer, pH 7.4 
in ratio of 1:10 followed by centriftigation at 16,000xg for 20 minutes at 4°C and 
washing as described above. 
For the preparation of sealed membrane vesicles, the unsealed membrane 
vesicles were resuspended to a final volume of 40 ml in 5 mM sodium phosphate 
buffer, pH 7.4 containing 150 mM NaCl and incubated at 37°C for 40 minutes 
followed by centriftigation at 16,000x:g for 20 minutes at 4°C. The pellet, thus 
obtained, was collected and used as such in ftirther studies. 
Heterogeneous membrane vesicles were prepared by washing the unsealed 
membranes with 5 mM sodium phosphate buffer, pH 7.4 contaming 10"* M 
MgS04 followed by centriftigation at 16,000xg for 20 minutes at 4°C. The pellet 
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was resuspended in the same buffer to a final volume of 40 ml and incubated at 
37°C for 40 minutes followed by centrifugation at 16,000xg for 20 minutes at 
4°C. 
Inside-out membrane vesicles were prepared from the unsealed membrane 
vesicles after washing them with 0.5 mM sodium phosphate buffer, pH 8.2 
followed by centrifiigation at 16,000xg for 20 minutes at 4°C. The pellet, thus 
obtained, was resuspended in 40 volumes of the same buffer and kept for 18 
hours on ice. The membranes were pelleted at 16,000xg for 20 minutes at 4°C 
and resuspended again in the same buffer. Then contents were homogenized on a 
vortex, passed three to four times through No. 27 gauge needle followed by 
centrifugation at 16,000xg for 20 minutes at 4°C and the pellet collected. 
The pellets of all types of membrane vesicles were finally suspended in 5 mM 
sodium phosphate buffer, pH 7.4 and used immediately for bilirubin binding 
studies. 
(c) Sealed and human serum albumin (HSA)-entrapped sealed human 
erythrocyte membranes were prepared by employing the buffer system used by 
Steck & Kant (1973) with a little modification. Erythrocytes prepared, as above 
were hemolysed in cold 5 mM sodium phosphate buffer, pH 8.0 (5P8) in a ratio 
of 1:40. The membranous ghosts were pelleted by centrifugation at 16,000xg for 
20 minutes at 4°C followed by subsequent washes with the same buffer as 
described above. These washes were performed till milky white morphologically 
mtact unsealed membranes were obtained. 
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To 5.0 ml of these unsealed membranes was added 3.0 ml of 20 % HSA 
solution prepared in 5 mM sodium phosphate buffer, pH 8.0 containing 10"^  M 
magnesium sulfate (5P8-MgS04). Another set was prepared where HSA was 
substituted with 5P8-MgS04. The two suspensions were then dialyzed 
extensively (overnight) against the same buffer with frequent changes. Under 
these conditions, membranes resealed and trapped albumin inside. Both the 
suspensions were washed with the same buffer and pelleted by centrifiigation at 
16,000xg for 20 minutes at 4°C. The supernatant was checked after every wash 
for protein content. Washing was performed till no protein content was detected 
in the supernatant and the volume was made upto 8.0 ml with the same buffer. 
This resulted in the formation of HSA-entrapped sealed human erythrocyte 
membranes and sealed human erythrocyte membranes, respectively. These 
preparations were maintained in the same buffer (5P8-MgS04) and used 
immediately for ftirther studies, hi order to check the feasibility of resealing, 
sealed membranes prepared in the same way as described above were incubated 
with the similar- amount of albumin used earlier and kept overnight under the 
same conditions mentioned. The preparation was then centrifiiged at 16,000xg 
for 30 minutes and washed with 5P8-MgS04 till the protein content in the 
supernatant becomes negligible. These membranes were used as such for 
bilirubin binding studies employing CD spectroscopy. 
The amount of HSA trapped inside the sealed membranes was determined 
from the difference of protein content of HSA-enfrapped membranes and sealed 
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membranes after digesting both the preparations in 1% SDS and estimating 
protein content by the method of Lowry et al. (1951). 
13. Enzymatic and other treatments of erythrocyte membranes 
(a) PhosphoHpase C treatment of erythrocyte membranes was performed 
according to the method of Sato et al. (1987). To 0.5 ml of membrane suspension 
(~ 4 mg protein/ml) in 50 mM tris-HCl buffer, pH 7.4 was added 4.25 ml of 0.1 
M tris-HCl buffer, pH 7.4, 50 \i\ of 1.0 M CaCb and 200 ^1 of the enzyme 
solution (0.15 mg/ml) and the mixture was incubated for different time periods at 
37°C. After a desired period of incubation, all the contents were centrifiiged at 
16,000xg for 20 minutes at 4*^ 0 and the released phosphate (Pi) in the 
supernatant was measured by the method of Fiske & Subbarow (1925). The 
treated membrane pellet was washed once with cold 50 mM tris-HCl buffer, pH 
7.4 containing 10 mM EDTA followed by centrifiigation at 16,000xg for 20 
minutes at 4°C. This reaction mixture for the binding assay became turbid during 
the mcubation with phospholipase C and turbidity increased with time. 
(b) Phospholipase D digestion of erythrocyte membranes was carried out 
following the method of Sato et al. (1987). To 0.5 ml of erythrocyte membrane 
suspension was added 1.4 ml of 0.1 M tris-HCl buffer, pH 7.4 and 100 [il of 
enzyme solution (9.3 units). The mixture was incubated for different time periods 
at 37°C. After the desired period of incubation, the contents were centrifiiged at 
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16,000xg for 20 minutes at 4°C. The supernatant was assayed for released 
choline by the method of Kates & Sastiy (1969). 
(c) Ghost suspension (0.5 ml) was digested with neuraminidase (2 units) for 
different time periods at 37°C in 1.0 ml of 0.1 M tris-HCI buffer, pH 7.4 (Sato et 
al, 1987). The mixture was centrifiiged at 16,000xg for 20 minutes at 4°C after 
desired incubation and the supernatant containing released sialic acid was 
collected and subjected to sialic acid estimation as described by Warren (1959). 
(d) The percentage accessibility of sialic acid in different membrane vesicles 
preparations to neuraminidase was determined by the method of Stack & Kant 
(1973) after treating the membranes containing 100-300 |xg protein in 50 [il with 
neuraminidase (0.1 mg/ml) for 30 minutes at 25°C both in the presence and 
absence of 0.2% (v/v) Triton X-100. The released sialic acid was determined 
directly by the method of Warren (1959). 
(e) Method of Steck et al. (\971) was used for tryptic digestion of erythrocyte 
membrane which was performed by incubating 0.5 ml of membrane suspension 
with 1.0 ml of 2.5 mM tris-HCI buffer, pH 8.1 containing 5 mg of solid trypsin at 
37°C and the mixture was shaken gently to dissolve the enzyme completely. 
After the desired time of incubation, the mixtures were centriftiged at 16,000xg 
for 20 minutes at 4°C and the released glycopeptides in the supernatant were 
measured for carbohydrate content according to Svennerholm (1956). 
(f) Membrane suspension (0.5 ml) was incubated with different volumes of 
1.0 M CaCl2 in 50 mM tris-HCI buffer, pH 7.4, making the total volume of 1.5 
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ml, for about 30 minutes at 37°C. Unbound metal ions were removed by 
centrifligation of the membranes at 16,000xg for 20 minutes at 4°C. 
Treated membranes stated above (a-f) were washed with cold 50 mM tris-HCl 
buffer, pH 7.4 twice followed by centrifligation at 16,000xg for 20 minutes at 
4°C and the fmal pellet, thus obtained, was resuspended in the same buffer after 
making up the volume to 1.0 ml. These preparations were directly used for 
bilirubin binding experiments. 
(g) Various other treatments of human erythrocyte membranes were carried 
out by the procedure described by Kahlenberg (1972). Membranes (1.0 ml in 50 
mM tris-HCl buffer, pH 7.4) were treated separately with DMMA (20 mg/ml of 
incubation mixture), 0.1 mM EDTA (pH 8.0), 20 mM LIS, 1.0 M Nal and 1.0 
mM NaOH (pH 11.5) in a total volume of 4.0 ml for 1 hour at 37°C. The 
supernatant and pellet fractions were separated by centrifligation at 16,000xg for 
20 minutes at 4°C. The pellet, so obtained, was washed twice, with either 50 mM 
tris-HCl buffer, pH 7.4 or 5 mM sodium phosphate buffer, pH 7.4 and suspended 
in 1.0 ml of the same buffer. 
(h) Oxidative cross-linking of erythrocyte membrane proteins was carried out 
according to the method of Kahlenberg (1972). To 1.0 ml of membrane 
suspension in 50 mM tris-HCl buffer, pH 7.4 was added 1.0 ml of the solution 
containing 100 |uM o-phenanthroline and 20 jiM CUSO4 The total volume was 
made to 4.0 ml with the same buffer and incubated for 1 hour at 37°C. Half of 
these samples received 100 mM 2-mercaptoethanol after 30 minutes of 
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incubation and further incubated for additional 30 minutes. Membrane pellets 
obtained by centrifiigation were washed in the same way as described above and 
used directly for bilirubin binding experiments. 
14. Extraction and analysis of phospholipids 
Untreated and phospholipase C-treated membranes were subjected to 
phospholipid extraction by the method of Gier & Deenen (1961). To 1.0 ml of 
membrane suspension was added 5.0 ml of isopropanol with intermittent 
shaking. After 2 hours, 2.0 ml of chloroform was added and the suspension was 
kept overnight at 10°C. The supernatant, obtained by centrifiigation at 16,000xg 
for 20 minutes, was dried under reduced pressure in a rotary evaporator, washed 
thrice with benzene and finally dissolved in 500 jil of chloroform. 
The phospholipids, thus obtained, were separated by two-dimensional thin-
layer chromatography following the method of Dittmer & Wells (1969) on silica 
impregnated aluminium sheets (20x20 cms) using a pair of solvents introduced 
by Rouser et al. (1969). Phospholipid extracts (1-5 \ig of lipid phosphorus) are 
applied in a 1 cm diameter spot in one comer located 3 cm from each edge of the 
silica impregnated aluminium sheet. Application of too much lipid in a very 
small area at the origin usually leads to spot elongation and streaking. The lipids 
were applied in a 20-30 \i\ volume at one time. Ascending chromatography was 
carried out at 23°C in a constant temperature room. The sheet was placed in a 
developing jar containing 105 ml of solvent I (chloroform, methanol, 28% 
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ammonia in a ratio 65:35:5, respectively). The chamber was sealed with a lid and 
the chromatogram is developed. After the first run, the chromatogram was dried 
for 30 minutes at room temperature and the second dimension was run at right 
angles to the direction of the first solvent in a sealed jar containing 104 ml of 
solvent II (chloroform, methanol, acetone, acetic acid and water in the ratio 
60:12:24:12:6, respectively). 
Detection of phospholipid spots: 
After the chromatogram was developed, it was dried at room temperature for 30 
minutes and finally placed in a jar of iodine for the detection of the phospholipid 
spots. Since spots fade on drying, it was found usefiil to circle the spots with a 
pencil. 
Each spot produced was scraped off and collected in separate tubes. It was 
then eluted with 5.0 ml of chloroform-methanol mixture (1:1) for 2 hours and the 
eluent was evaporated in a boiling water bath. Each sample was subjected to 
inorganic phosphorus estimation by the method of Ames & Dubin (1960). The 
phospholipid content was estimated by multiplying the total inorganic 
phosphorus content by 25 as suggested by Berg (1969). 
15. Bilirubin binding experiments 
Bilirubin solution was prepared by dissolving a few crystals of bilirubin in 38 
mM sodium carbonate solution containmg 5 mM EDTA, pH 11.0. The 
concentration of bilirubin solution was determined by Fog's method (Fog, 1958). 
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However, for bilirubin binding study with CaCb-treated membranes, EDTA was 
excluded from the solubilization medium. Following procedures were adapted 
for studying the binding of bilirubin to erythrocyte membranes. 
(a) Binding of bilirubin to erythrocyte membranes at different pH was studied 
by addition of different volumes (20-250 |il) of stock bilirubin solution to 1.0 ml 
of albumin solution of known concentration in 50 mM tris-HCl buffer having pH 
X (where X= 7.0, 7.2, 7.4, 7.6 or 7.8) to get different bilimbin/albumin molar 
ratios, B/As (0.5-3.0) and the volume was made up to 1.25 ml with 50 mM tris-
HCl buffer having same pH as that of albumin solution. Then, 250 ^1 of 
erythrocyte membrane suspension in the same buffer was added and the tubes 
were incubated for 30 minutes at 37°C after gentle shaking, hi another set of 
experiments, both the bilirubin and albumin concentrations were varied to obtain 
a constant B/A (bilirubin concentration varying from 100-400 |iM). 
(b) Effect of temperature was studied by pre-incubating the membrane 
suspension in 50 mM tris-HCl buffer, pH 7.4 and biiirubin/albumin mixture of 
different B/As, independently at different temperatures (i.e., 7°C, 20°C, 27°C, 
37°C, 40°C, 50°C and 60°C) for 30 minutes followed by mixing of 
biiirubin/albumin solution with membrane suspension and further incubation for 
30 minutes at their respective temperatures. 
(c) Binding of bilirubin to different erythrocyte membrane vesicles was 
studied by taking different volumes (40-400 fil) of albumin stock solution in 5 
mM sodium phosphate buffer, pH 7.4 and adding increasing volumes (40 - 250 
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\xl) of stock bilirubin solution to achieve a B/A of 2:1 and the volume in each 
tube was made up to 1.0 ml with the same buffer. Then 500 (J.1 of erythrocyte 
membrane vesicles (4.7 mg protein per ml) was added and the tubes were 
incubated for 30 minutes at 37°C after gentle shaking. 
(d) Binding of bilirubin to erythrocyte membranes (untreated/treated) was 
studied by incubating 1.0 ml of the membrane preparation in a final volume of 
1.5 ml containing 250 fil of bilirubin (150 nmoles for experiments with 
phospholipase C and CaCl2-treated membranes and 225 nmoles for other treated 
membranes) and 250 |J.1 of albumin solution in 50 mM tris-HCl buffer, pH 7.4 to 
achieve a B/A of 2.0. The mixture was incubated for 30 minutes at 37°C. 
(e) Binding of bilirubin to native and protein-depleted membranes was 
studied in 50 mM tris-HCl buffer, pH 7.4 after incubating these membranes (0.5 
ml) with bilirubin (150 ^M) in a total volume of 4.0 ml for 30 minutes at 37°C. 
(f) Binding of bilirubin to sealed and HSA-entrapped sealed erythrocyte 
membranes was studied by CD spectroscopy. The bilirubin binding experiments 
were performed in 5P8-MgS04. The bilirubin solution was prepared by 
dissolving a few crystals of bilirubin in 1.0 ml of 38 mM sodium carbonate 
solution, pH 11.0 and immediately diluted with 5P8-MgS04. The spectral 
measurements were made after incubating 1.0 ml of membrane preparations (3.8 
mg/ml of sealed and HSA-entrapped sealed) with 1.0 ml of bilirubin solution 
(150 fiM) for 1 hour at 37°C. The spectra were recorded under dim/yellow light. 
All these experiments were performed at least thrice. 
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Bilirubin-loaded membranes obtained by centrifugation at 16,000xg for 20 
minutes at 4°C in each of the above experiments, were washed 3-4 times with the 
same buffer used in their experimental protocol followed by centrifugation at 
16,000xg for 20 minutes at 4°C until the last supernatant was devoid of yellow 
color. The membrane-bound bilirubin was estimated in the same way as 
described earlier (Tayyab «fe Ali, 1999) which is based on the determination of 
bilirubin as "azobilirubin" using Fog's method (1958) after SDS solubilization of 
membranes. The method is sensitive to measure a minimum amount of 3 nmoles 
of bilirubin in a given sample of 1.0 ml. 
Bilirubin-bound membranes were solubilized in 1% (w/v) SDS (to a final 
volume of 1.5 ml) by incubating the contents at 60°C for one hour and Fog's 
reaction was carried out with 1.0 ml of the solubilized membranes to determine 
bilirubin concentration. The turbidity formed due to SDS was removed by 
centrifiigation at 6000xg for 20 minutes. 
Statistical analysis of the data included calculations of dispersion. Difference 
of means were tested for significance using two-tailed 't' test. The 't' values were 
used to calculate the P-value. 
16. Drug binding studies 
Ceftriaxone (29.8 mg) and sodium salicylate (0.72 mg) were dissolved in 5.0 ml 
of 5P8-MgS04. These solutions were protected from light and used within one 
hour. Binding of drug to sealed and HSA-entragped sealed erythrocyte 
Y ' ' ;• 
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membranes was studied both in the absence and presence (300-1200 fiM) of 
drugs. To the incubation mixture, prepared above for bilirubin binding studies, 
was added 1.0 ml of 5P8-MgS04 or drug (ceftriaxone/sodium salicylate). After 
incubation for 1 hour at 37°C, the CD spectral changes were observed. 
17. Circular dichroism (CD) spectroscopy 
CD spectra (of native, treated, sealed and HSA-entrapped membranes) in the 
absence as well as presence of bilirubin were recorded on a Jasco-
spectropolarimeter, model J-720, equipped with a microcomputer. The 
instrument was calibrated with d-10 camphorsulfonic acid. All measurements 
were carried out at 25°C with the help of a thermostatically controlled cell holder 
attached to a Neslab RTE-110 circulating water bath with an accuracy of ±0.1°C. 
Spectra were collected at a scan speed of 20 nm/min and with a response time of 
1 second. Each spectrum was the average of four scans. Far-UV CD spectra were 
taken in the wavelength range of 200-250 nm using quartz cuvettes of 1 mm 
path-length. The bilirubin and protein concentrations in these samples were 
150 )j.M and 0.51 mg in a volume of 4.0 ml incubation mixture, respectively. CD 
values were transformed into molar ellipticity [0]^ ^ using the following 
relationship: 
[0K = e . M R W / l O . l . c (11) 
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where, 9 is the observed elUpticity in degrees, c is the protein concentration in 
g/cm ,^ 1 is the pathlength in cm and MRW is mean-residue weight taken as 114.3 
g/mo\ (Chen etal., 1974). 
The visible-range CD spectra were measured in the wavelength range of 350-
550 nm at 25±0.1°C using a cell holder of 10 mm pathlength. The spectra were 
collected at a scan speed of 500 nm/min with a response time of 1 second. Each 
spectrum was the average of three scans. The bilirubin and protein concentrations 
used in this region were 150 |aM and 1.0 mg in a volume of 3.0 ml incubation 
mixture, respectively. 
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RESULTS AND DISCUSSION 
Isolation of serum albumin 
Serum albumins of human and goat were isolated as described in the 
experimental section. About 2 grams of protein was obtained from 100 ml of the 
plasma. These preparations were found to be homogeneous as they gave a single 
symmetrical peak on 8 % polyacrylamide gel (Figure 13) showing a fair degree 
of charge homogeneity. 
Electrophoretic pattern of human and goat erythrocyte membranes 
Figure 14A (1) shows the electrophoretic pattern of human erythrocyte 
membrane polypeptides as visualized by coomassie dye on 10 % polyacrylamide 
gels in 1 % sodium dodecyl sulfate. The electrophorogram represents the six 
major bands constituting two thirds of the protein staining profile as given by 
Fairbanks et al. (1971). These bands were numbered according to Fairbanks et al. 
(1971) as Components I and II (mol wt. approx. 250,000) which form a slow 
moving doublet while Component III predominates with mol wt. 89,000. Then 
there is Component IV (mol wt 77,500), Component V (41,000) and Component 
VI (mol wt. 36,200). Fairbanks et al. (1971) have divided these components into 
two classes, components I, II, V and VI compose the class of proteins related to 
membrane by possible ionic bonds. The other class includes components III, IV 
and sialoglycoproteins, and these polypeptides are tightly bound to membrane. 
Goat erythrocyte membrane stained with coomassie blue (Figure 14A, 2) shows 
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Figure 13. Electrophoretic pattern (Native-PAGE) of goat serum 
albumin (well 1) and human serum albumin (well 2) on 8% 
polyacrylamide gel under non-denaturing conditions. About 10 ng of 
goat serum albumin and 30 p,g of human serum albumin protein was 
loaded into each well, respectively. TD represents the position of 
tracking dye. 
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Figure 14. Electrophorogram (SDS-PAGE) of human 
erythrocyte membrane (1) and goat erythrocyte membrane (2) on 
10% polyacrylamide gels in 1% sodium dodecyl sulfate as visualized 
by coomassie blue stain (A) and carbocyanin stain (B). TD represents 
the position of tracking dye. 
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an almost similar pattern of polypeptides however, an additional band designated 
as gp 155 (mol wt. 155,000) by Inaba & Maede (1988) is visible between the 
bands 1 + 2 and band 3, which is a transmembrane glycoprotein. 
Visualization of the human and goat erythrocyte membrane polypeptides with 
carbocyanin dye (Figure 14B, 1 and 2, respectively) resulted in the staining of 
sialoglycoproteins PAS I, II and III as blue bands. The most prominent of these 
PAS bands in human erythrocyte membrane electrophoretic profile has a 
molecular weight of 83,500 (Fairbanks et al., 1971). 
Different age group red blood cell membranes 
Interaction of bilirubin (150 i^M) with the erythrocyte membranes of different 
age groups shows maximum binding of bilirubin to old erythrocyte membranes 
(114.8 nmoles/mg phospholipid) and minimum with young erythrocyte 
membranes (59.6 nmoles/mg phospholipid). The difference in the amount of 
bound bilirubin was found to correlate negatively with sialic acid content and 
phospholipid content (as is evident from Table I), which is maximum (21 nmoles 
and 1.365 mg, respectively) in case of young erythrocytes and minimum (13 
nmoles and 0.810 mg, respectively) in case of old erythrocyte membranes. Aging 
results in decrease of resistance to membrane permeability, which may account 
for the old cells sequestering more bilirubin. Moreover, reduction in the total 
sialic acid content per cell (Seaman et al., 1977) connected with the loss in 
membrane surface area appears to determine minor repulsive forces (Danon & 
Marikovsky, 1988). The penetration of bilirubin into the cell membrane is 
Table I 
Comparison of bilirubin bound to different age groups of human 
erythrocyte membranes. 
Age group Phospholipid Sialic acid Bound Bound bilirubin/rag phospholipid 
content content bilirubin 
(mg) (nmoles) (nmoles) (nmoles/mg phospholipid) 
YOUNG 1.365±0.23 21.0±1.2 81.4±1.3 59.6±4.2 
MIDDLE 1.145±0.12 18.0±2.2 86.4±2.2 75.5±4.2 
OLD 0.810±0.23 13.0±2.3 93.0±1.1 114.8±5.2 
Each reading is the mean of six independent observations. 
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Figure 15. Electrophorogram (SDS-PAGE) of dijfferent aged 
group red cell membranes, unfractionated (1), young (2), middle (3) 
and old (4) as visualized by coomassie blue staining (A) and young 
(1), middle (2) and old (3) red blood cell membrane fractions as 
visualized by carbocyanin staining (B). 
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facilitated in senescent erythrocytes as compared to younger cells, due to 
diminished surface-charge density. The younger cells are more susceptible to 
crenation while older cells show increase in susceptibility to hemolysis at higher 
bilirubin concentration (Brites et al, 1997). 
The electrophoretic pattern as observed with coomassie stain showed no 
significant difference in the protein content and their specific polypeptide bands 
(shown in Figure 15 A, 1, 2, 3 and 4) however, carbocyanin staining (Figure 15 
B) did show slight variation in their sialic acid content as evident by the 
reduction in the intensity of blue bands, signifying the position of glycopeptides. 
Cohen et al. (1976) also showed that sialic acid content decreases consistently 
with cell age. More of high molecular weight proteins in older cells due to 
peroxidation of lipids and lesser amounts of bands 1 and 2 proteins (spectrin) 
have been reported earlier (Balduni et al, 1974) and phospholipid phosphorus 
has been reported to decrease (Westerman et al, 1963) along with protein, which 
also decreases from top to bottom fraction i.e. increasing cell density (Rahman et 
al, 1973) as seen from figure 15A (4). The biochemical profile of unfractionated 
cells is comparable with young and middle cell fraction (Cohen et al, 1975). The 
young, middle and old erythrocyte membrane fractions (Figure 15A, 2, 3 and 4) 
have been compared with unfractionated cell membrane loaded into another well 
(Figure 15 A, 1). 
The differences between the membrane glycoproteins of a very young and a 
very old erythrocyte must be much more evident than those shown in our resuhs 
where significant differences in the binding of bilirubin to different aged group 
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cells is shown (the p-value of young versus middle, 0.0022; middle versus old, 
0.0005 and young versus old 1.32x10'^ ). Since the young and old 'ghosts' 
fractions, each correspond to about 10 % of the total erythrocyte population and 
it was not possible to isolate the cells just entered into the circulating blood from 
those that were going to be destroyed. 
Interaction of bilirubin with erythrocyte membranes at different pH 
At a given pH, increase in the B/A from 0.5 to 3.0 led to an increase in the 
membrane-bound bilirubin (Figure 16). This increase was smaller up to a B/A of 
1.5:1 but became more significant (P<0.05) at high B/As at all the pH values 
used in this study. Nearly two-fold (P<0.05) increase in membrane-bound 
bilirubin was noticed on increasing the B/A from 1.0 to 2.0. At all the five 
different pH values, i.e., 7.0, 7.2, 7.4, 7.6 and 7.8, the patterns of bilirubin 
binding to membranes were qualitatively similar. However, the amount of 
membrane-bound bilirubin at any B/A in the range of 0.5 to 3.0 was different at 
different pH values, being negatively correlated with pH of the medium, hi other 
words, lowering the pH from 7.8 to 7.0 resulted in increased binding of bilirubin 
to erythrocyte membranes at all the B/As tested even at B/As below 1:1. hi an 
earlier study, cellular binding of bilirubin has also been shown to vary with pH in 
the same fashion (Bratlid, 1972b). 
At a given constant B/A (i.e. 2:1), the binding of bilirubin to erythrocyte 
membranes increased linearly with increase in bilirubin concenfration at all the 
pH values used (as shown in Figure 17). Similar results were found with other 
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B/As. Linear increase in bound bilirubin with the increase in biUrubin 
concentration in incubate at a constant B/A and pH was also observed earlier 
with human erythrocytes (Hayer et al, 1989; Tayyab & Ali, 1997). hicrease in 
membrane-bound bilirubin per unit increase in bilirubin concentration in incubate 
was calculated from the slope values of the straight-line plots obtained at 
different pH values and at different B/As. This slope value was found to be 
different for different pH values and different B/As, being highest at pH 7.0 
(Figure 18). However, at B/As 2.5 and 3.0, the value of slope became constant 
between pH 7.4 and 7.0. In other words, the increase in membrane bound 
bilirubin per unit increase in bilirubin concentration in incubate was similar 
between pH values 7.4 and 7.0 at B/As 2.5 and 3.0. As the binding of bilirubin to 
erythrocytes and erythrocyte membranes follows a Michaelian saturation curve 
(Tayyab & Ali, 1995; Hayer et al, 1989), the slope value calculated from curves 
shown in figure 17 will depend on the range of free bilirubin concentration 
available in the incubate in such a way that with the increase in the range of free 
bilirubin concentration, the change in the slope value will be minimum. For 
example, at pH 7.4, the difference in slope value obtained was maximum 
between B/As 2.0 and 1.5 followed by between 2.5 and 2.0 whereas the value 
was minimum between B/As 3.0 and 2.5 (see figure 18). Since the available 
range of free bilirubin concentration at B/A 1.5 is minimum whereas it is 
maximum at B/A 3.0, these results are in accordance with the above explanation. 
One possible factor for the higher binding observed at pH 7.0 compared to pH 
7.4 or higher may be the large uicrease in free bilirubin concentration in the 
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incubate at pH 7.0 compared to pH 7.4 due to decreased albumin binding as 
reduced binding of bilirubin to albumin has been shown earlier by different 
workers after lowering the pH from 7.4 to 6.5 (Odell et al, 1969). Another factor 
may be the increased susceptibility of erythrocyte membranes towards bilirubin 
at lower pH. This is because decrease in pH may convert bilirubin dianion (B '^) 
to monoanion (BH'), which seems to be responsible for the increased binding of 
bilirubin to membranes at lower pH (Vazquez et al, 1988). It may be noted that 
out of the three species of bilirubin i.e., bilirubin dianion (BH^"), bilirubin 
monoanion (BH") and bilirubin acid (BH2), erythrocyte membranes are capable 
of binding both BH2 and BH" (Vazquez et al, 1988; Brites et al, 1997). Keeping 
in view all the above points, consistency in the slope value observed in the pH 
range 7.4-7.0 at higher B/As (2.5 and 3.0) can be ascribed to a higher free 
bilirubin concentration in the incubate. Since membrane binding of bilirubin is 
significantly increased with decreasing pH even at lower B/A i.e. 1.5, the results 
shown here are of clinical significance as B/A of as high as 1.37 has been 
reported in jaundiced neonates (Cashore & Oh, 1982) and also in the presence of 
various bilirubin displacing ligands including drugs, the B/A may reach a higher 
value which may be fatal under acidosis conditions. 
Interaction of bilirubin with erythrocyte membranes at different 
temperatures 
fricubation of erythrocyte membranes with bilirubin at different temperatures 
ranging from 7°C to 60°C showed that at any given B/A above 1:1, the amount 
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of membrane-bound bilirubin was greatly influenced by the temperature of the 
incubation medium as shown in figure 19. Within the temperature range of 27°C 
to 37°C, the amount of membrane-bound bilirubin at any given B/A above 1:1 
was found to be minimum. Increase in temperature on either side led to an 
increase in bilirubin binding to erythrocyte membranes at all B/As. Sato & 
Kashiwamata (1983) also reported minimum binding of bilirubin to eiythrocyte 
membranes at 37°C using a B/A of 2.0. A comparison of bilirubin binding 
patterns of human erythrocyte membranes at different temperatures and B/As 
shows that at each temperature, the binding was higher at higher B/As. This 
unusual behavior of bilirubin binding to erythrocyte membranes at different 
temperatures may be either due to the effect of temperature on the binding of 
bilirubin to albumm or due to the change in the physical state of bilirubin binding 
sites of the erythrocyte membranes. The lipid bilayer of human erythrocyte 
membrane exists in gel state below 18.5°C while above 40°C it mainly exists in 
liquid crystalline state (Barenholz & Thompson, 1980). Cestaro et al (1983) 
have reported that in the gel state both disordered phospholipid bilayers and 
protrusion of apolar regions of membrane proteins highly increased the 
hydrophobicity of outer sides of the membranes which greatly potentate the 
binding of bilirubin to the membranes. On the other hand, above 40°C, the 
membranes are in liquid-crystalline state and the lipids are randomly arranged 
(Vigh et al, 1998) and both the surface area per molecule and bilayer spacing are 
increased due to the hydration of phospholipids (Barenholz & Thompson, 1980). 
Under such conditions, bilirubin can freely penetrate the internal apolar core of 
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the membrane bilayer from both surfaces (Hayward et al, 1986). However, 
within the temperature range of 20-40°C, the arrangement of lipid in the bilayer 
of the membrane is not random, i.e. most of the choline phospholipids are 
confined to the outer while negatively charged phospholipids to the irmer surface. 
Under such condition, it is likely that the interaction of bilirubin with the outer 
surface is more favorable than that of the inner surface, which may account for 
the low binding of bilirubin within the temperature range of 20-40°C. In addition 
to this, role of temperature in decreasing the bilirubin-albumin interaction 
thereby increasing the free bilirubin concentration for binding to the membranes 
cannot be ruled out. 
Differential accessibility of bilirubin to erythrocyte membrane vesicles 
bearing different structural features 
Figure 20 shows the results of binding of bilirubin to different human erythrocyte 
membrane preparations at a fixed bilirubin/ albumin molar ratio (2:1) but at 
increasing concentrations of bilirubin (120-380 \xM). As is evident from the 
figure, increase in the concentration of bilirubin in the incubate mixture led to an 
increase m the membrane-bound bilirubin in all types of membrane preparations. 
Although, the pattern of increase was similar in all types of membrane 
preparations, they showed quantitative differences in the amount of bound 
bilirubin. Maximum binding of bilirubin was found in unsealed membranes 
followed by heterogeneous and sealed membrane vesicles whereas minimum 
binding of bilirubin was observed in case of inside out membrane vesicles. 
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Statistically, the difference in the amount of membrane-bound bilirubin between 
unsealed and heterogeneous, heterogeneous and sealed as well as sealed and 
inside out vesicles was found highly significant (P<0.05). The analysis of 
bilirubin binding data to inside out and sealed vesicles suggest that the inner 
surface of the membranes are able to bind some amount of bilirubin indicating 
the presence of few bilirubin binding sites on the inner surface of the membranes. 
However, the bilirubin binding sites presence on the outer surface of membranes 
seem to be comparatively large in number than that of inner surface. This 
assumption is further justified by the observations that the binding of bilirubin to 
unsealed membranes in which both the inner and outer layer of the membranes is 
available for bilirubin binding, bind more bilirubin than the sealed membranes in 
which only the outer layer is available for bilirubin binding. Further, comparison 
of bilirubin binding to heterogeneous membranes (i.e., mixed population of 
unsealed and sealed membranes) with that of unsealed and sealed shows that the 
binding is lower than that of unsealed membranes but higher than that of sealed 
membranes suggesting that the assumption is in good agreement with the 
observed data. This order of bilirubin binding to different types of membrane 
preparations was found to correlate with the percentage accessibility of 
neuraminidase. The percentage accessibility of neuraminidase was in the order of 
89.7%, 83.3%, 78.9% and 42.1% for unsealed, heterogeneous, sealed and inside 
out membranes respectively. In all these membrane preparations the total sialic 
acid as well as the total phospholipid content was found more or less similar, 
suggesting that the difference in the binding of bilirubin to these erythrocyte 
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membrane preparations may be due to different structural features of membranes 
generated under different conditions. Since the released of sialic acid when 
treated with neuraminidase depend upon the availability of outer layer of the 
membranes as sialic acid is mainly located at the outer surface of bilayer, the 
binding of bilirubin to the different types of membranes species also seem to be 
depend upon the availability of outer layer of the membranes. In other words, it 
seems that greater the exposure of inner layer of membranes, more is the 
reduction in the binding of bilirubin to the membranes. This seems to be highly 
reasonable as the negatively charged bilirubin mono anion is reported to involved 
in the interaction of the membranes, therefore the exposures of high negative 
charge density on the inner surface of membranes due to presence of 
phosphatidic acid and phosphatidylserine will repel the binding of bilirubin to the 
inner surfaces. The binding of bilirubin to the outer surface will be more 
favorable as the presence of sialic acid on the outer surfaces of membranes have 
negligible impact on the binding of bilirubin to the erythrocyte membranes (Sato 
etal, 1987). 
Similar bilirubin binding pattern have also been found with the different types 
of membranes prepared from goat erythrocytes and is shown in figure 21. 
However, the amount of bound bilirubin was much less compared to that of 
human erythrocytes. Further, significant differences were observed only between 
the unsealed and inside out (P^ 0.002), heterogeneous and inside out (P= 0.01), 
sealed and inside out membrane vesicles (P= 0.02) whereas marginally 
significant differences was found between unsealed and sealed membrane 
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vesicles (P= 0.07). Estimation of percent accessibility of neuraminic acid also 
revealed that the percent sialic acid released in unsealed and heterogeneous 
membranes are nearly similar but marginally different from sealed and inside-out 
membrane vesicles. The different in bound bilirubin among different types of 
membranes preparations therefore was more or less positively correlated with the 
percent accessibility of neuraminidase to these membranes. As these experiments 
involving human and goat erythrocyte membranes were performed by taking 
similar volumes of membrane suspensions containing same amount of membrane 
protein, the differences in the binding of bilirubin to different types of membrane 
preparations between human and goat seem to be due to the difference in 
phospholipid composition of these membranes. As goat erythrocyte membranes 
have high content of sphingomyelin and little phosphatidylcholine compared to 
human erythrocyte membranes having high content of phosphatidylcholine 
(Barenholz & Thompson, 1980), this can account for the difference in the 
binding of bilirubin to these two types of membranes (also from table II). Earlier 
we have shown that maximum amount of membrane-bound bilirubin is 
hydrophobically inserted in the lipid bilayer which carmot be removed by the 
addition of albumin (Tayyab & Ali, 1999). Recalling that the interaction of 
bilirubin with sphingomyelin mainly involves hydrogen bonding (Zucker et al, 
1992) and dual nature of bilirubin binding to biomembranes in the form of 
dianion which binds weakly to the polar heads of the phospholipids and bilirubin 
acid binding sfrongly and is hydrophobically inserted into the apolar region of 
the bilayer (Cesltaro et al. 1983), it appears that phosphatidylcholine rich human 
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erythrocyte membranes are better candidates for bilirubin binding than goat 
erythrocyte membranes. This is supported by an earher finding that the amount 
of hydrophobically inserted bilirubin at a given time of incubation was found 
much lower in sphingomyelin containing membranes compared to 
phosphotidylcholine containing membranes (Eriksen et al, 1987). Further, 
higher rigidity of goat erythrocyte membranes due to high sphingomyelin content 
(Barenholz & Thompson, 1980) may act as a barrier in the hydrophobic insertion 
of bilirubin in these membranes. This is further supported by the fact that the 
uptake of amphiphathic molecules to human erythrocytes is much higher that 
than of goat erythrocytes (Farooqui et al, 1987). In spite of the differences in the 
amount of bilirubin binding to erythrocyte membranes of goat and human, the 
similar differences in the binding of bilirubin to different erythrocyte membrane 
vesicles of each species suggest either bilirubin binding sites of the erythrocytes 
membranes are mainly concentrated on the outer layer of membranes as 
suggested by Vazquez et al (1988) or both sides of the membranes are capable of 
binding bilirubin but the degree of bilirubin interaction were seems to be 
determined by the phospholipid compositions of each layer as suggested by 
(Zucker et al, 1992; 1994). In other words it seems that the outer layer of 
erythrocyte membranes having high content of PC and Sph were more 
susceptible to bilirubm compared to the inner layer of membranes containing 
high concentration of acidic phospholipids. 
Table 11. 
Choline phospholipids and sialic acid contents of human and goat 
erythrocyte membranes 
Human Goat 
Total phospholipid 348.2±7.9 319.p±13.5 
(ng/mg protein) 
Phosphatidylcoline* 130.6±2.8 11.3±0.5 
(ng/mg protein) 
Sphingomyelin* 86.0±2.0 146.4±6.2 
(ng/mg protein) 
Sialic acid** 44.p±1.7 25.9±0.9 
(nmoles/mg protein) 
*Both phosphatidylcholine and sphingomyelin of human and goat erythrocytes 
membranes are calculated from the total phospholipids using known percentage 
of these phospholipids contents (Barenholz & Thomson, 1980). 
** Sialic acid (nmoles/mg protein) is the total sialic acid release from (0.2% v/v) 
Triton X-100 treated membranes after incubation with O.lmg/ml neuraminidase 
for 30 min at 25°C. 
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Effect of phospholipases, neuraminidase, trypsin and CaCh 
The effect of phospholipase C (C welchii) treatment of human erythrocyte 
membranes can be seen from figure 22 where the amount of membrane Pi 
released is plotted against time of incubation of the membranes with the en2yme. 
A significant increase in the amount of released Pi was observed up to 40 min of 
incubation, which became constant thereafter. Using the value of total membrane 
Pi content (Table IV), the enzyme treatment resulted in the release of about 
62.3% of the membrane Pi. Similar enzymatic treatment of bilirubin-bound 
membranes (previously incubated with 450 nmoles of bilirubin at B/A of 2.0 and 
washed subsequently) showed a significant reduction in the amount of Pi 
released for the initial time periods up to 30 min. However, increase in the time 
of incubation up to 60 min was found to produce the similar release of membrane 
Pi as found with unbound membranes. Recalling that phospholipase C treatment 
of erythrocyte membranes results in the release of polar head groups from 
phosphatidylcholine (PC) and sphingomyelin (Sph) from the outer layer of 
erythrocyte membranes, the lesser release of membrane Pi in the early periods 
observed with bilirubin-bound membranes can be ascribed to the protective 
effect of bound bilirubin. It appears that removal of a few polar head groups of 
phospholipids from the outer layer facilitates the release of more Pi over a period 
of time, which seems to be hindered in the initial phase by the membrane-bound 
bilirubin. Extensive enzymatic freatment of the membranes led to enhanced 
packing of the ghosts, however, the cellular morphology is retained as suggested 
by Lenard & Singer (1968). 
Table III 
Chemical composition of human erythrocyte membranes (equivalent to 1,0 
ml of 50 % hematocrit value) 
Component Amount 
Protein (mg) 3.8±0.2 
Total phosphorus (Pi, i^g) 111 .7±4.2 
Organic phosphorus* (|ug) 53.0±1.7 
Phospholipid (mg) 1.3±1.7 
Sialic acid (nmoles) 119.5±8.7 
*Pi as determined in isopropanol-chloroform extracted phospholipids. 
Each value is the mean ± S.D. of twelve observations obtained with six different 
membrane preparations. 
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Figure 22. Time course of phospholipase C (C welchii) treatment 
of human erythrocyte membranes as monitored by Pi release. Open 
circles show the amount of Pi released upon enzyme treatment from 
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independent experiments. 
106 
Incubation of untreated as well as phospholipase C-treated human erythrocyte 
membranes with constant amount of bilirubin (150 nmoles at B/A of 2.0) led to 
an increase in the membrane-bound bilirubin. As much as 121% increase in 
membrane-bound bilirubin was noticed with the modified membranes treated 
with enzyme for 40 min (Figure 23). This increase in the membrane-bound 
bilirubin upon phospholipase C treatment correlated very well with the release of 
membrane Pi, which suggests that polar head groups of phospholipids play 
inhibitory role in the bilirubin-binding phenomenon. Even a very short (5 min) 
treatment of the membranes with phospholipase C resulted in 18% increase in 
membrane-bound bilirubin. These results were similar to the results observed by 
Sato and his group (1987). As phospholipase C treatment of bilirubin-bound 
membranes failed to release the bound bilirubin from these membranes, which 
otherwise resulted in the release of Pi, it appears that bilirubin binding to the 
membranes involves hydrophobic interactions. This is supported by an earlier 
finding, in which it has been suggested that bilirubin is hydrophobically inserted 
into the apolar region of the bilayer (Zucker et al, 1994). 
Degradation of phospholipids of human erythrocyte membranes by 
phospholipase C as analysed by thin-layer chromatography (Figure 24 and table 
rV) shows about 70% degradation of total phospholipids, which comprised of 
total degradation of Sph, 86% degradation of PC and 28% of 
phosphatidylethanolamine (PE) after 20 min of enzyme treatment. This suggests 
that exposure of diacylglycerols or ceramides potentiated a large increase in the 
membrane-bound bilirubin. 
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Figure 23. Effect of phospholipase C (Cwelchii) on the binding of 
bilirubin. Amount of bilirubin bound to phospholipase C-treated 
membranes is shown by closed triangles. Each point is the mean of 
two independent experiments. 
Inset shows the amount of bilirubin bound with increasing biluubui concentration 
in incubate mixture for different time periods of phospholipase C treatment, 0 min 
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Phospholipase D treatment of erythrocyte membranes for varying time periods 
was monitored by the estimation of choline released (Figure 25), as the enzyme 
is known to remove polar head groups from PC, PE and phosphatidylserine (PS) 
to produce phosphatidic acid. The enzymatic digestion of membranes for 60 min 
resulted in the release of 47.6 |j.g of choline/mg of protein, which corresponded to 
the degradation of about 45% of PC. Presence of bilirubin at the membrane 
surface, as observed with erythrocyte membranes pre-treated with 450 nmoles of 
bilirubin at B/A of 2.0, significantly inhibited the release of choline as 38.5% 
degradation of PC was noticed after phospholipase D treatment for 60 min. The 
lower extent of choline released from bilirubin-bound membranes observed at 
prolonged enzyme treatment can be attributed to the inaccessibility of enzyme 
cleavage sites due to bound bilirubin. Lack of difference in the amount of choline 
released from both normal and bilirubin-bound erythrocyte membranes at shorter 
incubation with the enzyme and the significant reduction in the amount of 
choline released from bilirubin-bound membranes compared to normal 
membranes at prolonged incubation of enzyme with these membranes suggests 
that release of few choline molecules from PC results in the clustering of 
bilirubin molecules around PC molecules, thereby, making some of the cleavage 
sites inaccessible to the enzyme. 
Bilirubin binding results obtained with phospholipase D-treated membranes 
at B/A of 2,0 (with 225 nmoles of bilinibin) showed 23%o increase in the bound 
bilirubin upon prolonged enzyme freatment (60 min) compared to untreated 
membranes (Figure 26). Although these results suggested the inhibitory role of 
Table IV 
Quantitative analysis of phospholipid degradation of human erythrocyte 
membrane by phospholipase C {C.welchii) under different time periods 
Time % Phospholipid recovered after treatment 
(min) 
Total PE PC Sph 
0 88.1±7.8 23.9±1.8 30.1±2.8 23.8±1.2 
20 26.4±6.0 17.0±2.8 4.3±1.8 
40 25.7±4.6 15.3±2.2 4.7±1.1 
60 26.5±4.6 17.2±2.1 4.2±1.6 
Each value represents the mean ± S.D. of six observations obtained with tliree 
different experiments. 
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Figure 24. Two-dimensional chromatogram of phospholipids from human 
erythrocyte membrane, visualized by iodine vapors before phospholipase C 
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dimension solvent. The numbers represent individual phospholipids, 
(1) Phosphatidylethanolamine (PE), (2) Phosphatidylcholine (PC), (3) Sphingomyelin 
(Sph), (4) Phosphatidylserine (PS), (5) Lysophosphatidylethanolamine (LPE) and (6) 
Lysohosphatidylserine (LPS). 
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Figure 25. Time course of phospholipase D (Cabbage) treatment of 
human erythrocyte membranes as monitored by choline release. 
Open circles (O) show the amomit of choline released upon enzyme 
treatment from normal membranes whereas closed circles ( • ) 
represent choline released from bilirubin-bound membranes. Each 
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polar head groups in bilirubin-binding to the membranes to some extent, 
bilirubin-binding results obtained with phospholipase C-treated membranes were 
found to be more convincing as 121% increase in bilirubin-binding was observed 
upon phospholipase C treatment against 23% increase in phospholipase D-treated 
membranes. From these results it appears that the presence of negative charge 
contributed by Pi restricts the bilirubin entry inside the hydrophobic milieu of 
membrane to a greater extent. In view of the stimulation of endogenous 
phospholipases (C and D) by receptor tyrosine kinases (Schmidt et al, 2000), 
growth factors (Shen et al, 2001), tumour necrosis factor a (Plo et al, 2000) etc., 
it is likely that membranes of various cells may be acted upon by these 
phospholipases and thus become more prone towards bilirubin toxicity. 
Therefore, activities of endogenous phospholipases should be checked to prevent 
bilirubin toxicity under jaundiced conditions. 
hicubation of human erythrocyte membranes with neuraminidase for varying 
time periods resulted in the release of sialic acid. Time course of neuraminidase-
treatment of erythrocyte membranes is shown in figure 27, which suggests that 
greater incubation of membranes with the enzyme led to a greater release of 
sialic acid that became constant after 60 min. A value of 84.1 nmoles of sialic 
acid / mg of protein (Table III) was determined for untreated membranes. This 
value was found to be higher than the value reported by Sato and his group (50.9 
nmoles of sialic acid / mg of protein) (Sato et al, 1987) but was in good 
agreement with the value reported by Choy et al (1979). Neuraminidase 
treatment for 2 hours resulted in the release of about 77% of sialic acid whereas 
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Figure 26. Effect of phospholipase D (Cabbage) treatment on 
binding of bilirabin. Amount of bilirubin bound to phospholipase 
treated membranes is shown by closed triangles (A) . Each point is 
mean of two independent experiments. 
Inset shows the amount of bilirubin bound with increasing bilirubin 
concentration at different time periods of phospholipase D treatment, 
0 min (• ) ; 10 min (»); 20 min (•) ; 40 min (° ); 50 min (*) and 60 
min (A) . 
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Sato et al. (1987) reported the release of 88% of sialic acid upon neuraminidase 
treatment. The possible discrepancy between our results and those reported 
earlier can be ascribed to the lower values of sialic acid in untreated membranes 
obtained by Sato and his group (1987). Effect of neuraminidase treatment on 
human erythrocyte membranes, visualized by carbocyanin staining of 
poly aery lamide gels is seen in figure 28. The blue bands signifying the position 
of PAS bands 1, 2 and 3 disappear even within 5 min of neuraminidase treatment 
(Figure 28A) and these correspondingly appear in the supernatant fraction along 
with other polypeptides obtained after centrifugation of untreated and treated 
membrane suspensions (Figure 28B). 
Bilirubin-bound membranes (preincubated with 450 nmoles of bilirubin at B/A 
of 2.0) produced the same results upon neuraminidase treatment as compared to 
those observed with control membranes. The only difference was observed in the 
initial phase (up to 20 min) of enzyme treatment where bilirubin-bound 
membranes showed some protection as judged by the lesser release of sialic acid 
from these membranes. It appears that the presence of bilirubin at the membrane 
surface offers some resistance to the enzymatic attack on some of the cleavage 
sites for the initial time period which also become accessible to the enzyme 
during prolonged enzyme treatment. 
Both membrane preparations (control as well as neuraminidase-treated for 
various time periods) were used for bilirubin binding studies after incubation 
with 225 nmoles of bilirubin at B/A of 2.0 and the results are shown in figure 29. 
As can be seen from the figure, 1 hour of enzyme treatment resulted in 41% 
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Figure 27. Time course of neuraminidase (C. perfringens) 
treatment of human erythrocyte membranes as monitored by siahc 
acid release. Open circles ( O ) show the amount of sialic acid 
released upon enzyme treatment from normal membranes whereas 
closed circles (•) represent sialic acid released from bilirubin-bound 
membranes. Each point is the mean of two independent experiments. 
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Figure 28. (A) Electrophorogram (SDS-PAGE) of the 
supernatant collected by centrifiiging neuraminidase (C 
petfrmgem)-tiQatQd membranes [5 min (1), 10 min (2), 20 min (3), 40 
min (4), 60 min (5), 120 min (6) and 180 min (7)] at 16,000xg for 20 
min at 4°C as visualized by carbocyanin staining. 
(B) Electrophorogram (SDS-PAGE) of human erythrocyte 
membranes after 5 min (1), 10 min (2), 20 min (3), 40 min (4), 60 
min (5) 120 min (6) and 180 min (7) of neuraminidase (C. 
perfringens) treatment as visualized by carbocyanin staining. 
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increase in the bound bilirubin compared to untreated membranes. This increase 
in bound bilirubin upon neuraminidase-treatment correlated to some extent with 
the release of sialic acid from membrane surface, which suggests some inhibitory 
role of sialic acid residues in the bilirubin-binding phenomenon to the 
membranes. Although these results are contradictory in terms of the increase in 
biUrubin binding upon neuraminidase-treatment with those of Sato and his group 
(1987) but agree very well in excluding the gangliosides as the candidates for 
bilirubin binding. 
Trypsin treatment of erythrocyte membranes resulted in the release of 
glycopeptides, which was monitored by carbohydrate measurement. Results of 
tryptic digestion of erythrocyte membranes are shown in figure 30A, in which the 
amount of carbohydrate released is plotted against time of incubation of enzyme 
with the membrane. As is clear from the figure, there was significant increase in 
the amount of carbohydrate released on increasing the time of incubation up to 
60 min beyond which it sloped off. As much as 74% of total membrane 
carbohydrate was released in 3 hours. When tryptic digestion of bilirubin-bound 
membranes (previously treated with 450 nmoles of bilirubin at B/A of 2.0) was 
performed under similar conditions, a slight decrease in the amount of 
carbohydrate released was noticed. This is understandable, as some of the tryptic 
cleavage sites of membrane proteins must have been protected by the bound 
bilirubin. Figure 31 shows the elecfrophoretic pattern of untreated and trypsin 
treated membranes for different time periods as visualized by coomassie and 
carbocyanin staining. Decrease in polypeptide bands (Figure 31 A) and 
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Figure 29. Effect of neuraminidase (C. perfringens) on the binding 
of bilirabin. Amount of bilirubin bound to neuraminidase-treated 
membranes is shown by closed triangles (A). Each point is the mean 
of two independent experiments. 
Inset shows the amount of bilirubin bound with increasing bilirubin 
concentration at different time periods of neuraminidase treatment, 
0 min (• ); 10 min (o ); 15 min (• ); 30 min (D ); 60 min (*); 
120min ( A ) and 240 min (» ). 
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Figure 30. (A) Time course of trypsin treatment of human 
erythrocyte membranes as monitored by carbohydrate release and its 
effect on the binding of bilirubin. Open circles (O) show the amount 
of carbohydrate released upon enzyme treatment from normal 
membranes whereas closed circles ( • ) represent carbohydrate 
released fiom bilimbin-bound membranes. Amount of bilirubin 
bound to tiypsin-treated membranes is shown by closed triangles 
(A) . Each point is the mean of two independent experiments. 
(B) Binding of tiypsin to human eiythrocyte membranes as 
monitored by the measmement of protein content in the membrane 
suspension shown as open triangles (A) . Each point is the average of 
two separate determinations. 
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Figure 31. (A) SDS-PAGE analysis of human erythrocyte 
membrane before (1) and after 15 min (2), 30 min (3), 60 min (4) and 
120 min (5) of trypsin treatment as visualized by (A) coomassie blue 
staining and (B, i) carbocyanin staining. 
(B, ii) Electrophoretic pattern of the supernatant collected before 
(1) and after similar time periods of trypsin treatment as figure 3 lA by 
centiiftiging at 16,000xg for 20 min at 4°C as visualized by 
carbocyanin staining. 
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glycopeptides (Figure 3IB, i) is visible by both coomassie and carbocyanin 
staining showing the effect of trypsin treatment of membranes for different time 
periods. A corresponding increase in the intensity of glycopeptide bands 
visuaHzed as blue (Figure 3IB, ii) is also evident from the figure in the 
supernatant fraction obtained by centrifrigation at 16,000xg for 20 min at 4°C. 
A significant increase in bilirubin binding to the membranes was noticed upon 
trypsin treatment when these treated membranes were incubated with 225 nmoles 
of bilirubin for 30 min. An analysis of bilirubin-binding data of freated 
membranes and untreated membranes showed about 57 % increase in the binding 
of bilirubin upon 3 hours trypsin treatment of the membranes (Figure 30A). 
These results were similar to those reported by Sato & Kashiwamata (1983) who 
suggested that the trypsin treatment of the membranes disclosed a great number 
of low-affinity bilirubin binding sites and that the bilirubin binding sites are not 
composed of proteins. 
These conclusions seem to be questionable in view of the retention of activity 
of membrane-bound trypsin (Burkholder & Brecher, 1972) which may cleave the 
albumin present in the incubation medium, thereby, increase the free bilirubin 
concentration in the incubation mixture, being accessible to the membranes. To 
check this possibility, we estimated the protein content both in untreated and 
trypsin-treated membranes. As trypsin treatment of the membranes is supposed to 
degrade the membrane proteins, one should expect a decreased protein content in 
trypsin-freated membranes compared to untteated membranes. Contrary to this, 
an increase in the amount of membrane protein was observed upon trypsin 
122 
treatment (Figure SOB), which suggested the binding of trypsin to the cell 
membranes. If this is really the case then incubation of these trypsin-treated 
membranes (with bound enzyme) with bilirubin-albumin mixture at B/A of 2.0 
for 30 min should degrade the albumin present in the medium. 
When both untreated as well as trypsin-treated membranes were incubated 
with bilirubin-albumin mixture under the conditions of biHrubin binding 
experiment and the supematants obtained after centriftigation was analysed by 
SDS-PAGE, significant degradation of albumin was observed as shown in figure 
32A. Further, it should be noted that trypsin treatment of the membrane for more 
than 1 hour did not result in any increase in membrane-bound enzyme activity as 
similar albumin degradative pattern was observed with all the three trypsin-
treated membranes (see figure 32A). This is also understandable fi*om figure 30B 
in which no further increase in membrane protein was observed after 1 hour of 
enzyme treatment. In order to verify these results, 3 hours trypsin-treated 
membranes were incubated with increasing concentrations of albumin and the 
supematants obtained after centriftigation were analysed by SDS-PAGE. The 
results are shown in figure 32B in which the intensity of low molecular weight 
degradative products was found to increase with the increase in albumin 
concentration in incubate. Taken together, all these results (Figures 30B, 32A 
and 32B) unequivocally suggest the degradation of albumin by the membrane-
bound activity found in trypsin-treated membranes. Therefore, degradation of 
albumin in the incubation mixture will certainly increase the fi-ee bilirubin 
concentration m the incubation medium, which may be available to the trypsin-
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Figure 32. (A) SDS-PAGE analysis of the supernatant obtained by 
centrifiigation of the incubation mixture containing untreated/trypsin-
treated erythrocyte membranes and bilirubin-albmnin mixture at B/A 
of 2.0. Lane 1 shows the resuh when untreated membranes were taken 
whereas lanes 2, 3 and 4 represent the results obtained with trypsin-
treated (1, 2 and 3 h, respectively) membranes. Lanes 5, 6 and 7 show 
the result when trypsin-treated membranes were incubated with 
bilirubin m the absence of albumin. 
(B) SDS-PAGE analysis of the supernatant obtained by 
centrifiigation of the incubation mixture containing 3 h trypsin-treated 
erythrocyte membranes and increasing concentrations of albumin. 
Lanes 1-7 show the results obtained when the concentration of 
albumin in the incubation mixture was 0, 25, 50, 75, 100, 125, 150 
HM, respectively. 
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treated membranes. In view of this, increased bilirubin binding to erythrocyte 
membranes upon trypsin treatment cannot be ascribed solely to the degradation 
of membrane proteins which have been suggested to act as a barrier in bilirubin 
binding to the membranes (Sato et al, 1987). From our results it appears that 
removal of carbohydrate from membrane surface exposes more surface area of 
the membrane for bilirubin to interact. 
The effect of Ca ions on the binding of bilirubin to human erythrocyte 
membranes was studied after incubating the membranes with different 
concentrations of CaCl2 in the range of 0-1.5 mM and then using these 
membranes after washing, for bilirubin-binding experiments. Incubation of Ca^ "^ -
treated membranes with 150 nmoles of bilirubin at B/A of 2.0 for 30 min resulted 
in an increase in membrane-bound bilirubin as compared to the amount of 
bound-bilirubin observed with control membranes. This increase in membrane-
bound bilirubin was dependent on CaCla concentration as the binding increased 
on increasing the CaCla concentration as shown in figure 33. As much as 85% 
increase in the amount of membrane-bound bilirubin was observed with 1.0 mM 
CaCl2 treatment beyond which it sloped off. The increase in bilirubin binding 
upon CaCl2-treatment can be ascribed to the shielding effect, redistribution of 
phospholipids as well as increase in surface hydrophobicity induced by calcium 
(Ito et al, 1975). It seems likely that this effect may also be mediated by 
endogenous phospholipases as activation of phospholipase C in nonexcitable 
cells has been shown to cause the release of Ca from intracellular stores 
(Kaznacheyeva et al, 2001). 
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In conclusion, these results suggest that polar head groups (phosphate in 
particular) of phospholipids along with carbohydrate and sialic acid produce 
hindrance in the binding of bilirubm to erythrocyte membranes. Further, binding 
of bilirubin to the membrane seems to be hydrophobic in nature. 
Interaction of bilirubin with native and protein-depleted human 
erythrocyte membranes 
Incubation of human er3^hrocyte membranes with alkaline ethylenediamine 
tetraacetic acid (EDTA) (0.1 mM, pH 8.0) resulted in the selective release of 
peripheral membrane proteins, namely, bands 1 and 2 as well as band 5 as shown 
in lane 2 of figure 34A and B. These results were in line with the previous reports 
(Kahlenberg, 1972; Fairbanks et al., 1971). Measurement of protein in the pellets 
obtained from native and EDTA-treated membranes suggested a release of 32 % 
of proteins upon EDTA treatment (see table V). Conformational analysis of 
erythrocyte membranes, both before and after EDTA treatment as studied by CD 
spectroscopy suggested significant retention of the CD spectral features in 
EDTA-treated membranes (see figure 35A and B and table VI). However, some 
additional CD bands at 205 and 208 nm appeared in modified membranes. 
Further, a slight decrease in the MRE values of the CD band minima (Table VI) 
were noticed in these membranes. Presence of minima around 223 and 208 nm 
were indicative of a-helical structure of membrane proteins. Binding of BR to 
these membranes (both native and modified) was studied both by quantification 
of membrane-bound BR and CD spectroscopy. A comparison of the values of 
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Figure 34. (A) Protein profiles of human erythrocyte membranes 
before (lane 1) and after treatment with 0.1 mM EDTA, pH 8.0 (lane 
2); 1.0 M Nal (lane 3); 20 mg/ml DMMA (lane 4); 20 mM LIS (lane 
5); 100 jiM phenanthroline + 20 |xM cupric sulfate (lane 6) and 
phenanthroline + cupric sulfate containing 100 ^M 2-mercaptoethanol 
(lane 7). 
(B) Protein profiles of released polypeptides as observed in the 
supernatant of native and treated human erythrocyte membranes. 
Various lanes represent the same order as shown in (A). 
(C) Protein profiles of 0.1 mM NaOH-treated erythrocyte 
membranes (lane 1) and released polypeptides (lane 2). 
About 25-35 ng of proteins were analysed electrophoretically on 10 % 
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membrane-bound BR obtained with native and EDTA-treated membranes 
suggested a small decrease (3%) in the membrane-bound BR upon EDTA 
treatment. Further, CD spectral analysis of the complexes of BR with these 
membranes showed more or less similar structural features with a red shift in one 
of the band minima and small decrease in ellipticity values (figure 35A and B, 
table VI). It can be interpreted from these results that the removal of peripheral 
proteins from the membranes did not affect the binding of BR significantly 
though, a slight alteration in membrane composition was observed as reflected 
from the significant red shift of the band minima at 214 nm. It should be 
mentioned that the removal of spectrin from the membrane may lead to 
destabilization of the membrane structure (Steck and Kant, 1973) which may 
account for the small decrease in BR binding and slight alteration in the CD 
signals. 
Electrophoretic analysis of the membrane pellet obtained as a result of alkali 
treatment of human erythrocyte membranes (see figure 34C, lanes 1 and 2) show 
the release of about 64 % (Table V) of membrane proteins. It appears that most 
of the extrinsic proteins are eluted with sodium hydroxide (NaOH) treatment 
since a number of protein bands were visible in the electrophoretic profile of the 
supernatant (see lane 2 of figure 34C). The CD spectrum of NaOH-treated 
membranes (Figure 35C) showed a significant decrease in ellipticity at band 
minima (223 nm) whereas a blue shift of 4 nm was observed in the band minima 
at 212 nm and appearance of a new band at 203 nm (Table VI). Decrease in 
ellipticities at 223 nm was more pronounced in NaOH-treated membranes 
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Figure 35. Far-UV CD spectra of human erythrocyte membranes 
before (solid line) and after the addition of 150 ^M bilirubin (dotted 
line) in 5 mM sodium phosphate buffer, pH 7.4 at a protein 
concentration of 0.513 mg/4nil. Various membrane preparations were: 
Native (A) 
Treatment conditions were the same as described in the legend to 
figure 34. 
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Far-UV CD spectra of human erythrocyte membranes before 
(solid line) and after the addition of 150 nM bilirubin (dotted line) in 5 
mM sodium phosphate buffer, pH 7.4 at a protein concentration of 
0.513 mg/4ml. Various membrane preparations were: 
EDTA-treated (B) 
Treatment conditions were the same as described in the legend to 
figure 34. 
Table V 
Effect of treatment of erythrocyte membranes with selective reagents on 
their protein content and bilirubin binding 
Membrane 
sample 
Protein concentration in pellet 
(mg/ml) 
Membrane-
bound 
bilirubin 
(nmoles) 
NATIVE 
EDTA-
treated 
NaOH-
treated 
LIS-treated 
"CuP-
treated 
"CuP-
mercaptoethanol 
treated 
DMMA 
treated 
Nal-treated 
3.08±0.19 
2.10±0.27 
1.12±0.14 
0.94±0.17 
2.37±0.14 
2.19±0.19 
1.29±0.17 
1.47±0.17 
100 
68 
36 
31 
77 
71 
42 
48 
114.0±0.82 
110.6±0.83 
99.6±0.50 
107.9±1.34 
105.3±0.66 
110.6±0.93 
119.3±1.26 
II5.9±0.80 
Each value is the mean of three individual experimental values. 
^CuP refers to o-phenanthroline-cupric sulfate cross-linked membranes. 
''CuP-mercaptoethanol refers to o-phenanthroline-cupric sulfate cross-linked 
membranes reduced with 2-mercaptoethanol. 
Table VI 
Circular dichroism data of native and treated human erythrocyte 
membranes before and after bilirubin binding 
Human erythrocyte Observed CD band minima/maxima. Position (nm) and 
membrane corresponding molar ellipticities in parenthesis 
(degcm dmot) 
NATIVE 
EDTA-treated 
NaOH-treated 
LIS-treated 
CuP-treated 
CuP-
mercaptoethanol 
DMMA-treated 
Nal-treated 
Bilirubin (-) 
223 
212 
223 
212 
208 
205 
223 
208 
203 
223 
218 
209 
205 
224 
208 
223 
209 
239 
233 
227 
247 
(-14710) 
(-12480) 
(-13820) 
(-11140) 
(-10700) 
(-4010) 
(-11140) 
(-8470) 
(-6240) 
(-5120) 
(-5120) 
(-5350) 
(-2670) 
(-13370) 
(-13370) 
(-13810) 
(-11590) 
(-2670) 
(-4900) 
(-2450) 
(-1670) 
Bilirub 
224 
214 
208 
224 
218 
209 
227 
223 
216 
209 
227 
221 < 
216 ( 
214 ( 
209 ( 
224 ( 
208 ( 
226 ( 
222 ( 
218 ( 
212 ( 
207 ( 
239 ( 
233 ( 
228 ( 
225 ( 
246 ( 
in (+) 
(-12030) 
(-9800) 
(-9800) 
(-9800) 
(-9360) 
[-7580) 
(-9800) 
(-10250) 
(-9360) 
(-8910) 
(-4460) 
(-4010) 
(-3570) 
(-3340) 
(-4900) 
(-11140) 
(-11140) 
(-10250) 
;-10700) 
;-9800) 
(-9360) 
(-10250) 
:+4900) 
:+5570) 
-1120) 
-3340) 
-780) 
Presence and absence of bilirubin is represented as (+) and (-), respectively. 
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compared to EDTA-treated membranes, suggesting gross conformational 
changes in NaOH-treated membranes. BR binding studies to these membranes 
showed a significant decrease (13 %) in BR binding (Table VI). This decrease in 
BR binding can also be seen jfrom the CD spectra of BR-membrane complexes in 
which the ellipticity at 209 nm was found to be similar to that obtained with 
treated membranes in the absence of BR. Presence of additional features at 227 
and 216 nm and abolishment of minima at 203 nm in the presence of BR 
indicated conformational alterations in the membranes (Figure 35C, table VI). A 
significant decrease in BR binding observed with NaOH-treated membranes 
seems to be understandable in view of the depletion of extrinsic polypeptides 
namely bands 1, 2, 5 and 6 as well as predominant inside-out orientation of these 
vesicles upon dilute alkali treatment (Jones & Nickson, 1981). This is because 
inside-out vesicles have been shown to bind lesser amount of BR as compared to 
right side-out vesicles (Rashid et al, 2000). 
Treatment of membranes with 3,5-diiodosalicylic acid, lithium salt (LIS) 
resulted in the release of a majority of polypeptides (lane 5 of figure 34A and B), 
which together constituted 69 % of protein (Table VI). These results were in 
accordance with earlier reports suggesting the release of bands 1, 2, 2.1, 4.2, 5 
and 6 from the membranes upon LIS treatment (Kahlenberg, 1972). LIS breaks 
the membrane into small vesicles and in addition to disrupting membranes it 
releases glycoproteins from the membranes (Kahlenberg, 1972; Marchesi & 
Andrews, 1971). Conformational analysis of LIS-treated membranes also 
revealed a marked decrease in ellipticity values at the band minima (223 nm) and 
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Far-UV CD spectra of human erythrocyte membranes before 
(solid line) and after the addition of 150 jiM bilirubin (dotted line) in 5 
mM sodium phosphate buffer, pH 7.4 at a protein concentration of 
0.513 mg/4ml. Various membrane preparations were; 
NaOH-treated (C) 
Treatment conditions were the same as described in the legend to 
figure 34. 
135 
appearance of more CD signals in comparison to untreated membranes (Figure 
35D, table VI). These changes in the CD spectra can be attributed to the marked 
alteration in membrane conformation upon release of various polypeptides. 
Contrary to this, when LIS-treated membranes were studied for BR binding, only 
6 % decrease in BR binding was noticed (Table V). Similarly, CD spectra of BR-
membrane complex, though showed the appearance of additional peaks but the 
ellipticity values were significantly decreased (Table VI). Greater retention in BR 
binding by LIS-treated membranes compared to NaOH-treated membranes 
suggest that some other factors (other than protein loss) were responsible for the 
decrease in BR binding to the membranes. 
In order to study the role of band 3 in the BR binding phenomenon, 
erythrocyte membranes were treated with o-phenanthroline and copper sulfate, 
(o-phenanthroline-cupric sulfate, CuP). This treatment resulted in the cross-
linking of band 3 proteins as evident from lane 6 of figure 34A in which the band 
3 protein was shifted to a higher molecular weight form. Also bands 1 and 2 were 
found to be cross-linked to a certain extent (see lane 6 of figure 34A). These 
results were in accordance with the earlier observations suggesting the cross-
linking of largely band 3 and bands 1 and 2 by an o-phenanthroline-cupric sulfate 
catalysed oxidation (Kahlenberg, 1972). About 23 % of the membrane proteins 
were lost in cross-linking experiments (Table V). Kahlenberg (1972) also showed 
a 25 % loss of ghost protein in their cross-linking experiments, CD spectra of 
cross-linked membranes showed strong a-helical characteristics as evident by the 
presence of two band minima at 224 and 208 imi with a slight decrease in 
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Far-UV CD spectra of human erythrocyte membranes before 
(solid line) and after the addition of 150 |iM bilirubin (dotted line) in 5 
mM sodium phosphate buffer, pH 7.4 at a protein concentration of 
0.513 mg/4ml. Various membrane preparations were: 
LIS-treated (D) 
Treatment conditions were the same as described in the legend to 
figure 34. 
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eJIipticity values (Table VI) as compared to native membranes. BR binding 
results obtained with these membranes indicated a smaller decrease (8 %) in BR 
binding as compared to native membranes. CD spectra of cross-linked membrane 
in the presence of BR also showed CD signals and ellipticity values comparable 
to native membrane (Figure 35E, table VI). 
The decrease in BR binding upon cross-linking of membrane proteins can be 
ascribed to either the loss of some membrane proteins or the formation of larger 
aggregates. To rule out the first possibility, reversal of the cross-linking reaction 
was carried out by reduction with 2-mercaptoethanol. That phenanthroline-
copper induced cross-linking is prevented in the presence of 2-mercaptoethanol 
is evident from the protein profile of native membrane with reference to band 3 
protein (lane 7 of figure 34A). However, 29 % loss (Table V) in protein content 
was observed upon this treatment, which was 6 % higher than the loss observed 
with cross-linking treatment in the absence of 2-mercaptoethanol. CD spectra of 
these membranes also showed more or less similar features with a slight decrease 
in ellipticity at 209 nm to those observed with cross-linking experiments (Figure 
35F, table VI). Presence of 2-mercaptoethanol resulted in the recovery of BR 
binding as these membranes showed 97 % binding of BR compared to 92 % 
observed with cross-linked membranes (Table V). This can also be seen from the 
CD spectra of the complexes of these membranes with BR (Figure 35F, table 
VI). Thus, it appears that the decrease in BR binding, noticed in cross-linked 
membranes, was due to the formation of larger aggregates rather than the loss of 
proteins. 
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Far-UV CD spectra of huinan erythrocyte membranes before 
(solid line) and after the addition of 150 ^ M bilirubin (dotted line) in 5 
mM sodium phosphate buffer, pH 7.4 at a protein concentration of 
0.513 mg/4ml. Various membrane preparations were: 
phenanthroline + cupric sulfate-treated (E) 
Treatment conditions were the same as described in the legend to 
figure 34. 
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Far-UV CD spectra of human erythrocyte membranes before 
(solid line) and after the addition of 150 |xM bilirubin (dotted line) in 5 
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0.513 mg/4ml. Various membrane preparations were: 
phenanthroline + cupric sulfate + 2-mercaptoethanol-treated (F) 
Treatment conditions were the same as described in the legend to 
figure 34. 
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Selective removal of the membrane proteins was also carried out by 
dimethylmaleic anhydride (DMMA) and sodium iodide (Nal) treatments. As can 
be seen from table V, about 58 % and 52 % proteins were released by DMMA 
and Nal treatments, respectively. This can also be seen from protein profiles of 
these membranes shown in lanes 3 and 4 of figure 34A and B, respectively. 
Similar loss of membrane proteins by these treatments has also been reported 
earlier (Kahlenberg, 1972). Majority of the proteins eluted by these treatments 
were peripheral proteins as shown in lane 3 and 4 of figure 34B. CD spectral 
analysis of these membranes showed unusual spectral features as bands were 
found to be red shifted towards the higher wavelength side (figure 35G and H as 
well as table VI). When these membranes were tested for BR binding slightly 
higher binding was noticed as compared to native membranes (Table V). CD 
spectra of the complexes were of complicated type. From these results it appears 
that the loss of proteins from these membranes by DMMA and Nal freatment 
changed the overall conformation of band 3 as the CD specfra of these 
membranes were totally different from those of LIS-treated membranes in which 
about 69 % of the total proteins were released helical spectral features were 
retained as shown by native membranes. This unusual perturbation in the 
membrane may account for the complete retention rather little higher BR binding 
properties as compared to native membranes. The disappearance of double 
minima reflects the loss of a-helical structure and the transition towards random 
coil. It can be assessed that the disruption of self-associated band 3 by DMMA is 
accompanied with a disruption of helical structure, thereby giving the impression 
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DMMA-treated (G) 
Treatment conditions were the same as described in the legend to 
figure 34. 
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(solid line) and after the addition of 150 ^ iM bilirubin (dotted line) in 5 
mM sodium phosphate buffer, pH 7.4 at a protein concentration of 
0.513 mg/4ml. Various membrane preparations were: 
Nal-treated (H) 
Treatment conditions were the same as described in the legend to 
figure 34. 
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that the CD spectrum of membranes was largely due to the folded structure 
maintaining a band 3-dimer (Makino & Nakashima, 1982). 
Taken together, all these results suggest that removal of membrane proteins 
does not affect the BR binding properties of erythrocyte membranes to an 
appreciable extent. These results strengthen previous findings (Sato & 
Kashiwamata, 1983; Nagaoka & Cowger, 1978; Cestaro et ai, 1983; Vazquez et 
al, 1988) suggesting that BR binding sites in the membranes are composed of 
lipids rather than proteins. 
Interaction of bilirubin with sealed and human serum albumin-
entrapped sealed membranes 
Free membrane and bilirubin (BR) exhibit no circular dichroism in the visible 
wavelength range of 350-550 nm (Gray et al, 1961) as seen from figure 36a and 
b, respectively. This is similar in case of free albumin and free drug (ceftriaxone 
and sodium salicylate), exhibiting no CD at wavelength above 300 nm however, 
bilirubin-bound sealed membrane (BR-sealed membrane) complex in the visible-
wavelength range of 350-550 nm shows bisignate CD spectra (Figure 37A) 
characterized by a positive CD cotton effect (CDCE) at higher wavelength and a 
negative CDCE at shorter wavelength. These observations are similar to those 
reported earlier (Lightner et al, 1986; Lightner et al, 1988) suggesting that the 
pigment binds to membrane in a folded conformation with positive chirality. BR-
protein complex gives biphasic spectra in the range 300-500 nm. The induced 
bisignate CDCE of BR-membrane complex (Figure 37A) for the long 
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wavelength transition shows a (+) long wavelength at 515 nm followed by (-) 
short wavelength CE at 470 nm with a shoulder at 430 nm and a small (+) short 
wavelength CE at 410 nm. A crossover point for major peaks is at 490 nm 
(Figure 37A). The appearance of major peaks (positive and negative) at these 
wavelengths is ascribed to the cumulative CDCE of BR interacting with a 
number of membrane proteins, thereby shifting the characteristic BR-protein 
peaks towards longer wavelength range but retaining their signs. Moreover, 
intercalation of BR into apolar region of membrane could alter protein-lipid 
interface of selected regions of membrane (Zakim & Wong, 1990). 
BR complexed with human serum albumin (HSA) shows CD spectra 
characterized by the bisignate CDCE having minima at shorter wavelengths 
(405-425 nm) and maxima at longer wavelengths (400-470 nm) (Harmatz & 
Blauer, 1975; Lightner et al, 1986; Lightner et al, 1988; Blauer et al, 1977). 
BR incubated with albumin-entrapped sealed membranes also exhibit the 
characteristic induced bisignate CD bands of BR-HSA complex with long 
wavelength transition maxima at 450 and 475 nm and minima at 415 nm with a 
shoulder at 390 nm complex (Figure 37C). A crossover pomt at 440 nm, also 
characteristic of BR'HSA, complex is seen. The spectrum of membrane-bound 
BR (Figure 37A) transformed slowly to that of HSA-bound BR (Figure 37C) 
suggesting that BR traverses through the membrane and is available to the HSA 
entrapped within the sealed membrane either from the iimer side of membrane or 
by passing all the way along into the space within sealed membrane, interacting 
with albumin. A number of peaks emerge as a result of the cumulative effect of 
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BR binding to HSA as well as membrane proteins. In HSA-entrapped sealed 
membranes the CDCE of BR-protein complex resembles more of BR-HSA 
complex, ascribed to the direction of BR towards the inner space where albumin 
is available, strengthening the idea that BR instead of remaining intercalated, is 
able to bypass the exterior half of the bilayer because BR binds with high affinity 
to albumin (Peters, 1985). Figure 37B shows the CD spectra of bilirubin binding 
to sealed membranes incubated with albumin and washed extensively to clear the 
possibility of albumin adsorption to the sealed membranes. The CD spectra, more 
or less, resembles that of bilirubin bound-sealed membranes with no positive 
peaks around 450-470 nm but negative peaks at around 430 nm and 460 nm, 
suggesting that albumin indeed gets entrapped within the sealed membranes. 
Further, their characteristic CD spectra is not because of the inefficiency of 
resealing resulting in the leaking of albumin from sealed membranes and its 
interaction with the available bilirubin to give the type of CD pattern visualized 
for albumin entrapped-sealed membranes but is in fact the resultant of the 
interaction of bilirubin with entrapped albumin implying that bilirubin traverses 
membrane bilayer. 
The incorporation of ceftriaxone (300-1200 p-M) and sodium salicylate (300-
1200 ^M) into the incubation mixture containing sealed membrane and BR, 
severely decreased the intensity of both positive and negative CDCE (Figure 38, 
i-iii and 38A, iv-vi). Figure 38A (i), (ii) and (iii) represent bilirubin interaction 
with sealed membranes after the addition of 300 |J,M, 900 p.M and 1200 i^M 
ceftriaxone while figure 38A (iv), (v) and (vi) represent interaction of bilirubin 
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Figure 38. (A) Visible-CD spectra of bilirubin-bound sealed membranes 
incorporated with different concentrations of ceftriaxone, (i) 300 i^M; (u) 900 
uM and (Ui) 1200 i^M and incorporated with different concentrations of 
sodium salicylate, (iv) 300 nM; (v) 900 ^M and (vi) 1200 nM for 1 hr in 5 
mM sodium phosphate buffer, pH 8.0 containing 1 mM MgS04. The protem 
and bilirubin concentrations in each sample were 3.8 mg/3 ml of mcubation 
mixture and 150 )iM, respectively. 
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with sealed membranes after addition of 300 \xM, 900 [iM and 1200 \xM. sodium 
salicylate. Comparing these CD spectra (Figure 3 8A, i-iii and 3 8A, iv-vi) with 
that of BR-sealed membranes (Figure 37A) shows that at the same concentrations 
of both drugs, the decrease in negative ellipticities (430-470 nm) is more 
significantly affected by ceftriaxone than by sodium salicylate. A considerable 
decrease in the magnitude of the peak at 515 nm and trough at 470 nm in sealed 
membranes upon addition of 1200 )iM salicylate/ceftriaxone is seen (Figure 3 8A, 
iii and 38A, vi). The HSA-entrapped sealed membranes incubated with BR 
(Figure 37C) when incorporated with ceftriaxone (Figure 39A, i-iii) and sodium 
salicylate (Figure 39A, iv-vi) also exhibit significant reduction in the intensity of 
positive and negative CDCE, the negative ellipticities being affected more. This 
effect is similar to that observed earlier (WooUey & Hunter, 1970) where 
addition of salicylate to 1:1 BR-albumin solutions resulted in decrease in 
intensity of both CD bands with the trough being affected more. The positive 
band at around 515 nm is not affected by the incorporation of drugs, however the 
negative bands from 390-435 nm and the positive bands from 450-475 nm are 
severely diminished at a 900 jxM concentration of ceftriaxone in BR-bound HSA-
entrapped membranes. However, higher concentration of ceftriaxone eventually 
diminished the positive band at around 515 nm (Figure 39A, i-iii), which even 
high concenfrations of sodium salicylate could not offer (Figure 39A, iv-vi). 
Only about 900 |xM of ceftriaxone brought about significant reduction in the 
negative bands whereas 1200 |iiM of sodium salicylate was required to bring 
about the same extent of negative band reduction. 
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concentrations of sodium salicylate, (iv) 300 pM; (v) 900 ^M and (vi) 1200 
tiM for 1 hr in 5 mM sodium phosphate buffer, pH 8.0 containing 1 mM 
MgS04. The protein and bilirubin concentrations in each sample were 3.8 
mg/3 ml of incubation mixture and 150 |xM, respectively. 
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The effect of salicylate on the binding of BR to albumin was less marked than 
ceftriaxone but a drug-induced BR displacement from albumin is observed in 
both the cases as evident from the loss of the CD bands characteristic of BR-
HSA complex. This leads us to conclude that drugs bind to the same sites as that 
of BR-binding and can perturb the conformation of BR-protein complex. Binding 
of salicylate by albumin is considerably weaker than ceftriaxone as evident by 
the fact that the maximal displacement factor (6) for ceftriaxone is 3.00 as 
compared to sodium salicylate whose 5 is 1.5 (Brodersen, 1978). Thus, large 
doses of sodium salicylate are required to displace BR from albumin (Brodersen, 
1974). Therefore, some drugs can displace BR at the same binding sites from 
albumin with their displacing action varying from one drug to another, also the 
mechanism of action on membrane may also differ for various drugs. 
Here we conclude that HSA-entrapped sealed membranes exhibit CD spectrum 
characteristic of BR-HSA complex because HSA has much higher affmity for 
BR and an internal solution of HSA acts as the driving force for BR influx. BR is 
expected to distribute between internal albumin, within the bilayer and the 
surface of the lipid bilayer. Hayward et al. (1986) have reported that internal 
albumin pools exert competitive influence for BR binding to membranes and this 
fact necessitates the movement of BR across the liposome bilayer, quantitatively 
substantiating the hypothesis that BR can pass through membrane system by 
simple diffusion. However, partitioning of BR between albumin and membrane 
suggest that BR has considerable freedom of motion in membrane and not 
oriented by membrane. There are no groups on BR to keep the molecule at the 
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interface so BR partitions more exclusively into membranes. Thus, supporting 
the idea that BR is embedded into apolar region of membrane (Leonard et al, 
1989). This seems more feasible as our results with drug-induced BR 
displacement from albumin could not revert the BR-HSA CD signals to BR-
membrane CD signals as expected if BR interacts with internal albumin. Since, 
this did not happen, it seems more likely that BR reaches the inner layer of the 
membrane bilayer and is available to albumin on the inner surface, thereby 
giving the CD signals characteristic of BR-HSA. 
Clinical implications can be postulated as albumin is reported to enter 
disrupted blood-brain barrier and thus an increased entry of BR into such 
membrane could aggravate kemicterus in infants. Drug therapy in this case 
would only release the albumin-bound BR increasing free BR concentration for 
interaction with membranes. This would pose serious clinical complication since 
the effect would be a combination of BR as well as drug binding to membranes, 
hi an attempt to reconcile these results and to fiirther delineate the mechanism 
whereby BR traverses cellular membranes this simple strategy utilizing CD 
spectroscopy was undertaken. 
BMlouraphy 
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Abstract 
Interaction of bilirubin with different types of erythrocyte membrane vesicles such as unsealed, heterogeneous, sealed 
and inside-out membrane vesicles prepared from human and goat erythrocytes was studied. Out of various types of 
membrane vesicles, in both species, unsealed membrane vesicles bound quantitatively higher amounts of bilirubin 
followed by heterogeneous and sealed membrane vesicles whereas inside-out membrane vesicles bound the lowest 
amount of bilirtibin. These differences in the amount of boiuid bilirubin to different membrane vesicles were correlated 
well with the percentage accessibility of sialic acid to neuraminidase in these membranes suggesting that bilirubin bound 
preferentially to the outer layer of erythrocyte membranes than the inner layer. Further, membrane vesicles prepared 
from human erythrocytes bound higher amounts of bilirubin than those prepared from goat erythrocytes. This can be 
ascribed to different phospholipid composition of these membranes. © 2000 Elsevier Science Inc. All rights reserved. 
Keywords: Bilirubin; Erythrocyte membranes; Goat; Human; Inside-oul vesicles; Sealed membranes; Unsealed membranes 
1. Introduction 
Binding of bilirubin, a catabolic prodtict of 
hemoglobin to bi'ain cells is considered the main 
cause of bilirubin encephalopathy in jaundiced 
neonates (Hansen and Bratlid, 1986). To unravel 
the mechanism of entry of bilirubin into brain 
cells, studies have been performed on the interac-
tion of bilirubin with biological membranes using 
ci'ythrocyte membranes as a model (Sato and 
Kashiwiimala, 198.1; Sato et ;il., 1987). Allhough 
huge numbci- o[' dala is available on the biliru-
bin-mcmbrane inlcraclion, no conclusion has 
been arrived at the mechanism of entry itnd local-
izaliott of bilirubin in the bilayer membranes. 
* Correspondmg author. Tel.; -1-91-571-701718; la.x: -)-91-
571-7010S1. 
E-i)i(iil address: blisamua(« nde.vsnl.nel.in (S. Tayviib). 
Whereas Hayer et al. (1989) reported that ery-
Ihrocyles ;md erythrocyte membranes having sim-
ilar phospholipid coiilent bind the same amount 
of bilirubin, Karp el al. (1985) on the other hand, 
showed moi'c binding of bilirubin to lysed ery-
throcyte membranes compared with intact ghosts 
suggesting that bilirubin binds to both sides in 
lysed membranes compared with only one side 
binding in intact ghosts. This is supported by the 
work of Sato et al. (1987) who found no differ-
ence in biliitibin biiitling to inside-out and righl-
sidc otil sealed membrane vesicles, suggesting 
similar distribution of bilirubin binding sites on 
both outer and inner surfaces of the membranes 
or if sites arc present in the membranes, they are 
accessible from both sides. Contrary to this, 
Vazquez et al. (1988) have reported the presence 
of bilirubin binding sites mainly in the outer layer 
of bilayer membranes. In yet another study, 
0742-8413,OO'.S - sec front matter 'C' 2000 Elsc\'ier Science Inc. All rights reserved. 
Pit; 50742-8413(00)00162-6 
Effect of pH and temperature on the binding of bilirubin 
to human erythrocyte membranes 
H RASHID, MOHAMMAD K ALI and S TAYYAB* 
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202 002, India 
^Corresponding author (Fax, 91-571-701081; Email, btisamua@nde.vsnl.net.in). 
Effect of pH and temperature on the binding of bilirubin to human erythrocyte membranes was studied by incu-
bating the membranes at difi'erent pH and tempciaturcs anti dcterniining tlic bound bilirubin. At all pH values, the 
amount of membrane-bound bilirubin increased with the increase in bilirubiii-to-albumin molar ratios (B/As), 
being highest at lower pH values in all cases. Further, linear increase in bound bilirubin with the increase in bili-
rubin concentration in the incubate was observed at a constant B/A and at all pH values. However, the slope 
value increased with the decrease in pH suggesting more bilirubin binding to membranes at lower pH values. 
Increase in bilirubin binding at lower pH can be explained on the basis of increased free bilirubin concentration 
as well as more conversion of bilirubin dianion to monoanion. Temperature dependence of bilirubin binding to 
membranes was observed within the temperature range of 7°-60°C, showing minimum Ijinding at 27°C and 37°C 
which increased on either side. Increase in bilirubin binding at temperatures lower than 20°C arid higher than 40°C 
can be ascribed to the change in membrane topography as well as bilirubin-albumin interaction. 
1. Introduction 
Bilirubin is a yellow pigment produced by the catabolism 
of haemoglobin. Under physiological conditions, bilirubin 
remains bound to serum albumin which carries it to the 
liver for further metabolism. However, when biliruhin-to-
albumin molar ratio (B/A) exceeds 1:1, free biliiubin 
binds to many types of cells including brain cells which is 
the cause of brain toxicity in premature neonates, a con-
dition called kernicterus or bilirubin encephalopathy. In 
addition, jaundiced neonates with low plasma pH have 
been reported to be at greater risk of developing bilirubin 
encephalopathy (Kim et al 1980). Interaction of bilirubin 
with cells or cell membranes is well documented (Bratlid 
1972; Sato et al 1987; Vazquez et al 1988; Hayer et al 
1989; Leonard et al 1989; Tayyab and Ali 1995, 1997) 
and it is commonly accepted that the toxicity of bilirubin 
depends on its passage across the plasma inembraiie ami 
its association with membrane lipids (Ali and Zakim 
1993; Zucker et al 1994). However, the way in which bili-
rubin interacts with biological membranes is not fully 
understood. Erythrocytes being simple have been commonly 
used to study the interaction of bilirubin with cells or cell 
membranes as a model system (Hayer et al 1989). Further, 
erylhrocyte-bound bilirubin has been suggested as a useful 
criterion for the risk of bilirubin encephalopathy in neo-
nates (Bratlid 1972). It has been reported that the inter-
action of bilirubin with the membranes is greatly influenced 
by the physico-chcnncal pi'operties of the interacting 
media such as pH and teiiiperature (Sate and Kashiwa-
mala 1983). Increased binding of bilirubin to biological 
membranes at physiological pH (i.e., 7-0-7-2) has been 
suggested to be due to increased precipitation of bilirubin 
on the surface of membranes (Cestaro et al 1983). How-
ever, Sato and Kashiwamata (1983) have reported that 
saturable bilirubin binding to erythrocyte membranes has 
a pH optimum at around pH 7-i. They have suggested that 
the cellular susceptibility at lower pH may be determined 
not only by the physical state of bilirubin but also by the 
physico-chemical conditions of bilirubin binding sub-
stances on the membranes. Vazquez et al (1988) sugg-
ested that the increase in bilirubin binding to membranes 
at lower pH was mainly due to hydrophobic inclusion of 
bilirubin into membranes rather than aggregation of bili-
rubin on the surface of membranes. On the other hand, the 
influence of temperature on the binding of bilirubin is still 
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SUMMARY 
In order to develop an animal model for /// vivo testing of the displacing action of vaiioiis 
drugs and for study of the bilirubin dci)osiiion in the brain, some nu)lecular properties of the 
semm albumin from ditVerent species i,e pig, cat, liuman, dog, sheep, guinea pig and rat were 
mvestigaled. These albumins were found to have dilVerences in molecular weight, Slokes 
radius and electrophoretic mobility They also showed diHerenl bilirubin binding characteristics 
when studied by spectroscopy and lluorescence (|uenching. It is therefore, necessary to consider 
the species ditTerences when results of animal experimentation arc used as a basis for the 
investigation of human kernicterus. 
Key Words: Serum albumin of various animals, bilirubin binding, bilirubin encephalopathy. 
INTRODUCTION 
Daig - induced bilirubin displacement from albunfin is a factor to be considered in the development 
of preventive strategies against lata! kernicterus in jaundiced newborn infants (I). As a result it is 
suggested that all dnigs for use in neonates and pregnant or lactaling women should be tested for 
their bilirubin displacing effects (2,3). Various methods such as the horseradish peroxidase method 
(4) and equilibrium dialysis (5) are used in the testing ol' driigs on bilirubin - albumin interactions 
under /// viiro conditions. Because of problems encountered in these assays such as insolubility, 
spectral interference or inhibition / acceleration of the reactions by some drugs, they have limited 
applications (6). Moreover, it is desirable to check the displacing elYect ol'lesl drugs //) vivo which 
is difficult to perform in newborn mt'ants. The use ol~a suitable laboratory animal model would be 
.Abbreviations: fiSA, human serum albumin; CSA, cat serimi albumin; SSA, sheep serum albumin; 
l'S.'\, pig serum albumin; DSA, dog serum albumin; RSA, rat serum albunVm; (iPSA, guinea pig 
serum albumin 
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